

1           **Cytoplasmic Colocalization of Granulins and TDP-43 Prion-like**  
2           **Domain Involves Electrostatically Driven Complex Coacervation**  
3           **Tuned by the Redox State of Cysteines.**

4  
5           Anukool A. Bhopatkar, Shailendra Dhakal and Vijayaraghavan Rangachari<sup>§†</sup>.

6           Department of Chemistry and Biochemistry, School of Mathematics and Natural Sciences and <sup>§</sup>Center for  
7           Molecular and Cellular Biosciences, University of Southern Mississippi, Hattiesburg, MS 39406

8  
9           <sup>†</sup> Corresponding author: Vijay Rangachari, 118 College Drive #5043, University of Southern Mississippi,  
10           Hattiesburg, MS 39406. Tel: 601-266-6044; email: vijay.rangachari@usm.edu

11  
12  
13           Running title: Liquid-liquid phase separation of Granulins and TDP-43

14  
15  
16  
17           **Key words:** granulin, progranulin, TDP-43, FTLD, ALS, liquid-liquid phase separation, stress granules.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 **Abstract**

32       Cytoplasmic inclusions containing aberrant proteolytic fragments of TDP-43 are associated with  
33 frontotemporal lobar degeneration (FTLD) and other related pathologies. In FTLD, TDP-43 is  
34 translocated into the cytoplasm and proteolytically cleaved to generate a prion-like domain (PrLD)  
35 containing C-terminal fragments (C25 and C35) that form toxic inclusions. Under stress, TDP-43  
36 partitions into membraneless organelles called stress granules (SGs) by coacervating with RNA and other  
37 proteins. We were interested in understanding if and how cysteine-rich granulins (GRNs 1-7), which are  
38 the proteolytic products of a genetic risk factor in FTLD called progranulin, interact with TDP-43. We  
39 show that extracellular GRNs internalize and colocalize with PrLD as puncta in the cytoplasm of  
40 neuroblastoma cells but show no presence in SGs. In addition, GRNs and PrLD undergo liquid-liquid  
41 phase separation (LLPS) by complex coacervation, or form aggregates via liquid-solid phase separation  
42 (LSPS); the dynamics in these phase transitions appear to be driven by the negative charges on GRNs and  
43 fine-tuned by the positive charges and the redox state of cysteines. Furthermore, RNA competes with and  
44 expunges GRNs from GRN-PrLD condensates, providing a basis for GRN's absence in SGs. Together,  
45 the results bring to bear unique mechanisms by which GRNs could modulate TDP-43 proteinopathies.

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

## 64 Introduction

65 Frontotemporal lobar degeneration (FTLD), originally called Pick's disease, is a progressive  
66 neurodegenerative disease that affects the frontal and temporal lobes of patients predominantly 45-65  
67 years of age (Bang, Spina, & Miller, 2015). The neuronal atrophy observed in these patients is associated  
68 with language impairments accompanied by behavioral and personality changes (Grossman, 2002;  
69 Seelaar, Rohrer, Pijnenburg, Fox, & van Swieten, 2011). Based on histopathological signatures, FTLD is  
70 subclassified into FTLD-TDP, FTLD-Tau, and FTLD-FUS (rare) (Bang et al., 2015; Irwin et al., 2015;  
71 Prasad, Bharathi, Sivalingam, Girdhar, & Patel, 2019). Nearly half of FTLD patients show the presence of  
72 neuronal and glial cytoplasmic inclusions of TAR DNA binding protein-43 (TDP-43) (Irwin et al., 2015)  
73 making FTLD-TDP a predominant category of the disease. Furthermore, 95% of sporadic amyotrophic  
74 lateral sclerosis (ALS) patients also show TDP-43 inclusions besides sharing common genetic etiologies  
75 with FTLD, making FTLD-TDP and ALS to be part of a clinicopathological continuum (Irwin et al.,  
76 2015). Molecular etiologies of familial FTLD are associated with mutations in microtubule-associated  
77 protein tau (*MAPT*) for FTLD-Tau and those in Progranulin (*GRN*), TDP-43 (*TARDBP*), Fused in  
78 sarcoma (*FUS*), and Hexanucleotide repeat expansion in *C9orf72* (*C9orf72*) for FTLD-TDP (Prasad et al.,  
79 2019; Seelaar et al., 2011; Sun & Chakrabarty, 2017).

80 TDP-43 is a 43 kDa protein that contains an N-terminal domain, two RNA recognition motifs  
81 (RRMs), and a prion-like, disordered, C-terminal domain enriched with low complexity sequences  
82 (PrLD) (François-Moutal et al., 2019; Prasad et al., 2019). Localized in the nucleus, TDP-43 is involved  
83 in a wide range of functions including transcriptional regulation, RNA metabolism, and splicing among  
84 others (Buratti & Baralle, 2008; Buratti et al., 2001; H. Y. Wang, Wang, Bose, & Shen, 2004). Under  
85 cellular stress such as heat shock, oxidative insults, inflammation (Herman Allison et al., 2019; Khalfallah  
86 et al., 2018) or nutrient starvation (Herman Allison et al., 2019), TDP-43 coacervates with mRNA and  
87 other proteins to undergo liquid-liquid phase separation (LLPS) and partitions into membraneless  
88 organelles called stress granules (SGs) (Khalfallah et al., 2018; Liu-Yesucevitz et al., 2010). SGs are  
89 reversible cytoplasmic assemblies formed in response to cellular stress to sequester and prevent mRNA  
90 transcripts from degradation or translation (Colombrita et al., 2009; Protter & Parker, 2016; Van Treeck et  
91 al., 2018). In pathological conditions, TDP-43 is translocated to the cytoplasm where it undergoes  
92 aberrant proteolytic cleavage to generate several C-terminal fragments (CTFs) of varying sizes including  
93 C35 (~35 kDa), C25 (~25 kDa), and C17 (~17 kDa) with the former two being the most abundant of them  
94 (L. M. Igaz et al., 2008; I. R. A. Mackenzie & Rademakers, 2008; Neumann et al., 2006; Y.-J. Zhang et  
95 al., 2009). These fragments are also known to be formed via alternative splicing to varying degrees (Xiao  
96 et al., 2015). Importantly, TDP-43 CTFs undergo aggregation to form toxic, insoluble inclusions in the  
97 cytoplasm which are the pathological hallmarks of ALS and FTLD patients (Lionel M. Igaz et al., 2009;  
98 Neumann et al., 2006). Despite the conspicuity of the TDP-43 CTF aggregates in patients, factors  
99 responsible for their biogenesis and subsequent roles in pathology remain poorly understood. Similarly,  
100 while the formation of biomolecular condensates is now well established for TDP-43 and other members  
101 of SGs such as hnRNP1 (Nunes et al., 2019; J. Wang et al., 2018), FUS (Nunes et al., 2019; Sama et al.,  
102 2013) and TIA1 (Gilks et al., 2004; Nunes et al., 2019), the link between SGs and amyloid formation for  
103 TDP-43 remains ambiguous, but one that could be key in neurodegenerative pathologies.

104 Another key protein implicated in FTLD is a 68.5 kDa secreted protein called progranulin  
105 (PGRN). The protein possesses pleiotropic functions including wound healing, tumorigenesis (Z. He &  
106 Bateman, 2003) and immunomodulation (Jian, Konopka, & Liu, 2013). In neurons, PGRN has been  
107 identified to play key roles in neuronal functions, lysosomal homeostasis, cell survival, and differentiation  
108 (Elia, Mason, Alijagic, & Finkbeiner, 2019; Gao et al., 2010; Gass et al., 2012; Zhiheng He & Bateman,

109 1999; Ryan et al., 2009; Tanaka et al., 2017; P. Van Damme et al., 2008), and has gained significant  
110 attention due to its link to neurodegenerative pathologies especially FTLD. About 30-50% of FTLD-TDP  
111 cases are of a heritable type with mutations in *GRN* underlying a majority of them (Chow, Miller,  
112 Hayashi, & Geschwind, 1999; van der Zee et al., 2007). The autosomal dominant heterozygous *GRN*  
113 mutations results in haploinsufficiency of the protein, which led to the conclusion that PGRN plays a  
114 neuroprotective role (Arrant, Onyilo, Unger, & Roberson, 2018; I. R. Mackenzie et al., 2011; Ward et al.,  
115 2017), while homozygous *GRN* mutations lead to neuronal ceroid lipofuscinosis (NCL), a lysosomal  
116 disease (Chitramuthu, Bennett, & Bateman, 2017; Ward et al., 2017). But for the genetic connection and  
117 haploinsufficiency, the precise mechanism by which PGRN may influence FTLD has not been  
118 established. In this context, the cysteine-rich, ~6 kDa modules called granulins (GRNs 1-7), which are the  
119 proteolytic products of PGRN (Zhu et al., 2002) have been of great interest to us for their potential roles  
120 in FTLD and other pathologies. It is now known that extracellular PGRN is endocytosed into the  
121 lysosome via a sortillin-mediated pathway to be processed by cathepsins into GRNs (C. W. Lee et al.,  
122 2017), which are thus speculated to possess lysosomal functions (Holler, Taylor, Deng, & Kukar, 2017;  
123 Root, Merino, Nuckols, Johnson, & Kukar, 2021). GRNs also function in a plethora of roles in normal  
124 cell biology (Park et al., 2011; Shoyab, McDonald, Byles, Todaro, & Plowman, 1990; Philip Van Damme  
125 et al., 2008) but possess opposing inflammatory properties to PGRN; while PGRN is anti-inflammatory,  
126 GRNs show pro-inflammatory properties (Zhu et al., 2002). During inflammation, PGRN secreted from  
127 activated microglia and astrocytes undergoes extracellular proteolysis by neutrophil elastases and other  
128 proteases to generate GRNs (Ungurs, Sinden, & Stockley, 2014). The fate of the extracellular GRNs on  
129 neuronal function and dysfunction remains unclear and we conjecture that they are taken up by neurons  
130 where they interact with TDP-43. Some support for this idea came from a report from Salazar and  
131 coworkers (Salazar et al., 2015) who showed that specific GRNs affected TDP-43 toxicity in a *C. elegans*  
132 model (Salazar et al., 2015). We also demonstrated that GRNs, 3 and 5, interact with and modulate the  
133 aggregation and phase behavior of TDP-43 PrLD *in vitro* (Bhopatkar, Uversky, & Rangachari, 2020).  
134 Furthermore, GRN immunopositivity observed in several regions of the brain in post-mortem Alzheimer  
135 disease and FTLD-TDP patients potentiates the significance of GRNs in pathology (Mao et al., 2017).  
136 Interestingly, acute inflammation has also shown to induce mislocalization and aggregation of TDP-43 in  
137 mice and cell culture (Correia, Patel, Dutta, & Julien, 2015), increasing the likelihood of its interaction  
138 with GRNs.

139 Here, we delve deeper into understanding the molecular factors that govern the interactions  
140 between GRNs and TPD-43 PrLD (termed PrLD hereafter). Our results show that extracellular GRNs-2, -  
141 3 and -5 internalize and colocalize with PrLD in the cytosol of neuroblastoma cells but do not partition  
142 into the SGs formed under stress with PrLD. In vitro experiments suggest that GRN-2 undergoes complex  
143 coacervation with PrLD to form liquid droplets in the oxidized state but promotes insoluble aggregates in  
144 the reduced state. Based on the empirical results from GRNs and their specifically designed mutations and  
145 chemical modifications, we conclude that the complex coacervation of GRNs and PrLD towards liquid  
146 droplet formation is driven by the negatively charged residues, while the increase in positively charged  
147 residues promote aggregation. Furthermore, we determine that the redox state of cysteines is a key  
148 modulator by fine-tuning liquid-liquid or liquid-solid phase separation of PrLD near counterbalancing  
149 electrostatic charge regimes. Additionally, we show that RNA displaces GRNs from the PrLD droplets  
150 that provides a possible reason for not observing GRNs within the SGs.


151

152

153 **Results**

154 **GRN-2 colocalizes with TDP-43 PrLD in the cytoplasm but not in stress granules.**

155 Unlike the GRNs generated in the lysosomes, the fate of those formed in the extracellular space  
156 remains unclear although transport to the cytosol has remained a possibility (Hoque, Mathews, & Pe'ery,  
157 2010; Mao et al., 2017; Park et al., 2011). The ambiguity surrounding the precise localization of GRNs in  
158 pathophysiology has hindered understanding their roles in norm and pathology (Holler et al., 2017;  
159 Plowman et al., 1992). We conjecture that extracellular GRNs are internalized in the neuronal cytoplasm  
160 and potentially interact with proteolytic fragments of TDP-43 modulating the latter in ALS and FTLN  
161 patients. To recapitulate this scenario, we utilized a simple pulse-chase assay with fluorophore-labeled  
162 GRNs (Holler et al., 2017). In this assay, SH-SY5Y cells transiently expressing a blue fluorescence  
163 protein tagged PrLD construct (PrLD-SBFP2) were pulsed with media containing 500 nM of HiLyte532-  
164 labeled GRN-2 after 24 h (post-transfection), and then chased for an additional hour (see Methods). The  
165 cells were then imaged under non-stress and stress (with NaAsO<sub>2</sub>) conditions (Fig 1). Under non-stress  
166 conditions, the transfected PrLD was observed in both the nucleus and cytoplasm (top panels; Fig 1a).  
167 Pulsing with GRN-2 showed internalization and colocalization with PrLD outside the nucleus (arrow;  
168 middle panels, Fig 1a). To see whether the colocalization was within or outside the lysosomes the cells  
169 were observed using a lysosomal marker which clearly indicted GRN-PrLD puncta outside the lysosomes  
170 (arrow; bottom panels, Fig 1a). Not surprisingly, to some degree, GRN-2 by itself was observed to be  
171 localized within the lysosomes as it is known to be present in them (yellow puncta; bottom panels, Fig  
172 1a). Fluorescence recovery after photobleaching (FRAP) of the puncta showed no recovery of PrLD  
173 suggesting the formation of insoluble aggregates (green, top panel; Fig 1c). The samples were also  
174 immunodetected in the presence of TIA1 antibody, a key SG marker (Kedersha et al., 2000). In the non-  
175 stress conditions, TIA1 was located in the nucleus while PrLD had a disperse presence throughout the cell  
176 (Fig S1a). As expected, TIA-1 was absent from the colocalized PrLD and GRN-2 puncta as would be  
177 expected under non-stress conditions (No stress; Fig S1d). Under stress conditions induced by sodium  
178 arsenite, the transfected PrLD in SH-SY5Y cells showed puncta outside the nucleus (arrow; top panels;  
179 Fig 1b), consistent with SG formation (Colombrita et al., 2009; Khalfallah et al., 2018). Surprisingly, the  
180 fluidity of SGs observed by FRAP of PrLD did not show recovery (orange, top panel; Fig 1c), although  
181 widely varying photo bleaching recovery rates for SGs have been reported in cellular models (Gasset-  
182 Rosa et al., 2019; C. Wang et al., 2020; Wheeler, Matheny, Jain, Abrisch, & Parker, 2016). Nevertheless,  
183 PrLD's presence in SGs was confirmed by the colocalization of PrLD with TIA1 with a Meander's tM1  
184 value of 0.59 (Fig S1b). Pulsing GRN-2 onto these




185

186 **Figure 1. Cytoplasmic co-localization of GRN-2 and PrLD.** Confocal microscopy images of live SH-  
 187 SY5Y cells under homeostatic or stress conditions. a) Blue fluorescent protein tagged PrLD (PrLD-SBFP2)  
 188 transiently expressed in SH-SY5Y cells alone and in the presence of Hilyte-532 labeled GRN-2 under non-  
 189 stress conditions, and b) the same reactions under stress induced by sodium arsenite. White arrows indicate  
 190 colocalized GRN-2 and PrLD puncta in the cytoplasm, while yellow arrows represent colocalization of  
 191 GRN-2 in lysosomes (Scale bar= 5  $\mu$ m). Visualization of nucleus and lysosomes were done by staining  
 192 with NucSpot® Live 650 and Lysoview™ 650 respectively c) Normalized intensities of fluorescence  
 193 recovery after photobleaching (FRAP) for puncta of PrLD alone (—) or colocalized PrLD-GRN-2 (—) in  
 194 under non-stress (top) or stress (bottom) conditions. d) Whiskers plot of Manders' tM1 calculated for the  
 195 colocalization of GRN-2 with PrLD using Fiji-ImageJ software. Each data-point represents the  
 196 colocalization score of an independent cell.

197 cells under stress showed colocalization of both the proteins as puncta in the cytoplasm and outside the  
 198 lysosomes (arrows; middle and bottom panels; Fig 1b). Here again, the colocalized puncta did not show  
 199 fluorescence recovery (green, top panel; Fig 1c). Furthermore, GRN-2 did not show colocalization with  
 200 TIA1 and PrLD suggesting that GRN-2 was not partitioned into the SGs (Fig S1d). In addition, two other  
 201 GRNs known to modulate PrLD's phase transitions (Bhopatkar et al., 2020), GRNs 3 and 5, also did not

202 show colocalization with TIA1 under stress conditions, but colocalized with PrLD under both non-stress  
 203 and stress conditions (Fig S1d-e). The colocalization of GRN-2 and PrLD was also statistically significant  
 204 with ~ 73% of the internalized GRN-2 found to be colocalized with PrLD under stress and ~ 68% under  
 205 homeostatic conditions (Fig 1d). The lack of fluorescence recovery observed for the truncated TDP-43  
 206 construct of PrLD within SGs could potentially suggest gelled material-like properties. To see if this is  
 207 the case, SH-SY5Y cells were transfected with the full-length wild-type TDP-43 (wtTDP43tdTomato) as  
 208 a control, which has been observed to being present within SGs with a full recovery upon photobleaching  
 209 (Fig S2) (Gasset-Rosa et al., 2019). In our experiments too, FRAP showed the expected recovery of SGs  
 210 as compared to the non-stress conditions (Fig S2), which suggests that SG assemblies containing PrLD  
 211 construct may indeed possess solid- or gel-like characteristics. Taken together, the data establish that  
 212 extracellular GRN-2 internalizes and colocalizes with PrLD in the cytoplasm but is not present within the  
 213 SGs.



214  
 215 **Figure 2. Sequences of granulins (GRNs) and TDP-43 under investigation.** a) TDP-43 PrLD construct  
 216 (residues 267-414) along with a hexa-histidine tag (highlighted) used in the study. b-d) Sequences of GRN-  
 217 2 (b), -3 (c) and -5 (d). Sequences of proteins are annotated with acidic (red) and basic (blue) residues, along  
 218 with the net charges on the respective proteins at neutral pH.

### 219 GRN-2 modulates the phase transitions of PrLD *in vitro*


220 The observation of cytoplasmic puncta of colocalized PrLD and GRN-2 decoupled from SGs,  
 221 prompted us to investigate their interactions in greater detail. TDP-43 is known to undergo dynamic phase  
 222 transitions depending on the cellular conditions to form either liquid condensates or solid aggregates  
 223 (Ciryam et al., 2017; Fang et al., 2019; Watanabe et al., 2020). Understanding the molecular grammar of  
 224 protein LLPS has revealed that weak, multivalent interactions between ‘stickers’ involving electrostatics,  
 225  $\pi$ - $\pi$  (between tyrosines) or cation- $\pi$  (between aromatic residues and arginines and lysines) that are  
 226 separated by scaffolds called ‘spacers’ (Choi, Dar, & Pappu, 2019; Choi, Holehouse, & Pappu, 2020; J.  
 227 Wang et al., 2018), are the main driving forces of condensate formation. Disordered proteins enriched in  
 228 one kind of charge will repel one another preventing self-coacervation but interaction with a partner

229 containing counter-charge would minimize repulsion and promote LLPS (Pak et al., 2016). These  
230 interactions are also observed to be the driving forces behind the self- and complex- (with RNA)  
231 coacervation of TDP-43 (Babinchak et al., 2020; Conicella, Zerbe, Mittal, & Fawzi, 2016; Li, Chiang,  
232 Chou, Wang, & Huang, 2018). However, the molecular determinants of heterotypic phase transitions of  
233 TDP-43 involving ligands vary depending on the partners and are still being discerned (Babinchak et al.,  
234 2020). Despite the lack of a canonical RNA binding domain, TDP-43 PrLD undergoes complex  
235 coacervation with RNA, which illustrates the prominence of aforementioned interactions in phase  
236 separation (Bhopatkar et al., 2020; Conicella et al., 2016; Lim, Wei, Lu, & Song, 2016). However, the  
237 phase transitions are dictated by the balance between weak, multivalent interactions that drive LLPS, and  
238 strong, high affinity interactions that mediate liquid-solid phase separation (LSPS) often observed among  
239 amyloid proteins. Our earlier investigations into the interactions of PrLD with GRN-3 and GRN-5  
240 showed that GRN-3 induces LSPS in both oxidizing and reducing conditions, while GRN-5 undergoes  
241 LLPS by complex-coacervation with PrLD (Bhopatkar et al., 2020). We conjecture that the disparity in  
242 the behavior of GRNs is due to the high net negative charge on GRN-5 (-6; six - and no + charges, Fig  
243 2d) as opposed to GRN-3 (-2; seven - and two + charges, Fig 2c) that counter-interact with PrLD's net  
244 charge (+2) (Fig 2a). It is also likely that the lack of positive charges on GRN-5 plays a role. Here, we  
245 extended these investigations to uncouple the molecular determinants of the complex coacervation by  
246 investigating GRN-2. All three GRNs, 2, 3, and 5 possess a similar number of negatively charged acidic  
247 residues (7, 6, and 6 respectively, Fig 2b-d) but vary in the number of positively charged basic residues  
248 (2, 4, and 0, respectively, Fig 2b-d), making GRN-2 ideal to investigate. The presence of structural  
249 disorder in proteins is known to be an implicit contributor to LLPS (Brangwynne, Tompa, & Pappu,  
250 2015; Majumdar, Dogra, Maity, & Mukhopadhyay, 2019; Muiznieks, Sharpe, Pomès, & Keeley, 2018;  
251 Uversky, 2017; Wright & Dyson, 2015); PrLD is largely a disordered region of TDP-43 while GRN-2 is  
252 also predicted to be disordered in the fully reduced state by IUPred2A platform (Fig S3a-b) (Erdős &  
253 Dosztányi, 2020; Mészáros, Erdos, & Dosztányi, 2018). This prediction was confirmed by biophysical  
254 characterization of GRN-2 which revealed a structure dominated by random coils in both redox-forms  
255 (Fig S4a), similar to GRNs 3, and 5 (Bhopatkar et al., 2020) (Fig S3c-d and S4e).

256 To probe the ability of GRN-2 in both redox forms to modulate phase transitions of PrLD, 40  $\mu$ M  
257 GRN-2 (oxidized form) or rGRN-2 (reduced form) were mixed with 20  $\mu$ M PrLD buffered in 20 mM  
258 MES, pH 6.0 and the samples were visualized by differential interference contrast (DIC) microscopy (Fig  
259 3a-c). Immediately upon coincubation of GRN-2 and PrLD, the sample phase separated into liquid  
260 droplets ranging between 2 and 12  $\mu$ m diameter (Fig 3a). The droplets also showed classic wetting  
261 behavior suggestive of their liquid-like characteristics (arrow; Fig 3b). The colocalization of proteins  
262 within the droplets was confirmed using orthogonal fluorophores, HiLyte405 (blue) and HiLyte647 (red)  
263 for GRN-2 and PrLD, respectively, as well as their liquid-like properties by coalescence and fusion of  
264 droplets (Fig 3b). In stark contrast, samples containing rGRN-2 and PrLD showed the formation of solid  
265 insoluble aggregates (Fig 3c) which also involved colocalization of both proteins (Fig 3d). These results  
266 indicate that GRN-2 in the oxidized form induced LLPS of PrLD, while the reduced form induced LSPS.  
267 Treatment of GRN-2-PrLD droplets with 1,6-hexanediol (HD), an agent that is known to disrupt weak  
268 hydrophobic interactions and dissolve droplets (Düster, Kaltheuner, Schmitz, & Geyer, 2021; Shulga &  
269 Goldfarb, 2003), showed persistence of the condensates even after treatment (top panels; Fig 3e) but with  
270 a ~40% reduction in the turbidity levels compared to pre-HD treated sample suggesting that some  
271 hydrophobic interactions contributed to LLPS. Similar treatment of HD to PrLD-RNA coacervates  
272 showed a ~25% decrease in turbidity reaffirming that LLPS involving the two was driven primarily by  
273 electrostatic interactions (middle panels; Fig 3e). In contrast, LLPS of PrLD induced by salt showed as



274 much as 90% of droplets dissolved with HD treatment (bottom panels; Fig 2e). Together, the data indicate  
 275 that the coacervation of GRN-2 and PrLD is likely driven largely by electrostatic interactions.



276  
 277 **Figure 3. Phase transitions involved in GRN-TDP-43 PrLD interactions.** a-d). DIC microscopy  
 278 images of a mixture containing 20 μM PrLD with 40 μM fully oxidized GRN-2 (a-b) or reduced rGRN-2  
 279 (c-d) in 20 mM MES, pH 6.0. GRN-2 undergoes LLPS with PrLD (highlighted with green box) that shows  
 280 the coalescence of droplets (a, dashed box) while rGRN-2 undergoes LSPS (saffron box). GRN-2 or rGRN-  
 281 2 labelled with HiLyte 405 (blue) and PrLD with HiLyte 647(red) were visualized using confocal  
 282 fluorescence microscopy which shows fusion of droplets for GRN-2 (white arrow; b) and deposition of  
 283 solid aggregates for rGRN-2 (d). e) A mixture containing 40 μM GRN-2 with 20 μM PrLD was treated  
 284 with 1,6-hexanediol (HD) to monitor its effect on the LLPS of the proteins which were quantified using  
 285 OD<sub>600</sub> pre- and post- HD treatment. Similar treatment was performed for condensates of 20 μM PrLD with  
 286 either RNA (50 μg/mL) or NaCl (150 mM). The turbidity values were normalized with respect to their  
 287 values pre-HD treatment. f) Phase diagram for GRN-2 or rGRN-2 with PrLD generated by varying the pH  
 288 (buffered with 20 mM ammonium formate at pH 4.5 or 20 mM MES at pH 6.0) and concentrations of the  
 289 respective proteins. g-h) Phase diagram for varying concentrations of GRN-3 and GRN-5 with 20 μM PrLD  
 290 at pH 4.5 (g) and pH 6.0 (h). i) Turbidity assay performed by titrating the self coacervates of 20 μM PrLD  
 291 (generated in presence of 150 mM NaCl) with increasing concentrations of GRN-2, GRN-3 or GRN-5. j)  
 292 Titration of complex coacervates of 20 μM PrLD (generated with 40 μM GRN-2 or rGRN-2) with  
 293 increasing concentration of NaCl (50-500 mM). k) The turbidity of 20 μM PrLD alone, or in presence of  
 294 40 μM GRN-2 or rGRN-2 measured as a function of temperature. The phase boundaries were established  
 295 by considering an OD<sub>600</sub> value of 0.14 as a cut-off for phase transitions. Scale bar represents 10 μm.

296  
 297 Then LLPS or LSPS phase boundaries were determined for GRN-2 and rGRN-2 with PrLD using  
 298 turbidimetric assays (Fig 3f-k). In all these experiments, LLPS and LSPS were differentiated based on  
 299 microscopic examination of the samples and phase boundaries established by considering an OD<sub>600</sub> value  
 300 of 0.140 a.u. as a cut-off for phase transitions (see Methods). To see if the negative charges drive GRN-  
 301 PrLD LLPS, phase separation was observed at two different pHs; at pH 6.0 where the acidic residues  
 302 have a net negative charge and at pH 4.5 where the acidic residues are close to being neutral. At pH 4.5,


303 no phase separation was observed for GRN-2 or rGRN-2 with PrLD (Fig 3f, pH 4.5) but at pH 6.0, the  
304 proteins underwent phase transitions uniformly at concentrations of 10  $\mu$ M GRN-2 or rGRN-2 in all PrLD  
305 concentrations tested (Fig 3f, pH 6.0). However, in stark contrast, under fully reducing conditions, co-  
306 incubations of rGRN-2 with PrLD showed LSPS. The phase diagrams of GRN-3, GRN-5 with PrLD  
307 reveal both similarity and disparity in their phase transitions as previously observed (Bhopatkar et al.,  
308 2020)(Fig 3g-h); In an acidic environment, neither GRN undergoes phase transition with PrLD (Fig 3g)  
309 similar to GRN-2. At pH 6.0, both oxidized and reduced forms of GRN-3 show LSPS exclusively, albeit  
310 with a delay (solid precipitates observed after  $\sim$ 24 h), while incubation with GRN-5 showed LLPS  
311 exclusively (Fig 3h) (Bhopatkar et al., 2020). Together, these results suggest that the negatively charged  
312 residues on GRNs (evident from GRN-5, and data from assays at pH 4.5) are significant contributors of  
313 the complex coacervation with PrLD while an increasing number of positive charges on the protein  
314 modulates the dynamics towards LSPS (as observed from GRN-2 and GRN-3). Furthermore, we also  
315 questioned if and how GRNs modulate the self-coacervation of PrLD in presence of 150 mM NaCl (Fig  
316 3i). Under oxidizing conditions, GRN-2 did not alter PrLD LLPS even at high concentrations whereas,  
317 under reducing conditions, rGRN-2 induced LSPS even at ten-fold lower stoichiometry (Fig 3i). Both  
318 redox forms of GRN-5 attenuated the phase transitions of PrLD at high concentrations suggesting a net  
319 repulsive interaction (Fig 3i). The attenuation of LLPS under reducing conditions could be attributed to  
320 the formation of hydrogen bonds from the free thiols (12 in GRNs) to polar residues (Ser, Asn) on PrLD,  
321 that results in stronger solute-solute interactions and concomitant LSPS. To further observe the effect of  
322 electrostatics on phase transitions, the effect of increasing salt concentrations was probed (Fig 3j) on the  
323 process. As observed previously (Bhopatkar et al., 2020), PrLD alone failed to phase separate below  
324 physiological salt concentrations (up to 150 mM NaCl). On the other hand, upon co-incubation with  
325 GRN-2, PrLD showed LLPS well below physiological salt concentrations while in the presence of rGRN-  
326 2 LSPS was observed (Fig 3j). The increasing salt concentration had no significant effect on phase  
327 transitions of PrLD co-incubated with either redox form of GRN-2, but an increased magnitude of phase  
328 separation was observed indicating the simultaneous presence of homo- and heterotypic condensates of  
329 PrLD within the sample (data not shown). Finally, the temperature dependence of PrLD-GRN-2 phase  
330 transitions was examined to establish the upper critical solution temperature (UCST) (Conicella et al.,  
331 2016; H. R. Li et al., 2018). As expected PrLD underwent self-coacervation in no salt conditions at 4 $^{\circ}$ C  
332 that was attenuated at 25  $^{\circ}$ C and above suggesting a UCST between these temperatures (Fig 3k). Co-  
333 incubation with GRN-2 increased UCST to  $>$  49  $^{\circ}$ C, while the sample with rGRN-2 showed LSPS in all  
334 the temperature range recorded (Fig 3k).

335

### 336 **Negatively charged residues in GRNs drive LLPS while the positively charged ones enhance LSPS.**

337 The pH dependence on phase transitions (Fig 3f) provided an important clue regarding the  
338 involvement of electrostatic interactions, especially the negatively charged residues. To further investigate  
339 these aspects, the phase behavior of the three granulins, GRN-2, -3, and -5 along with specific mutants of  
340 GRN-2 were investigated. As mentioned above, all three GRNs are isoelectronic with respect to the  
341 negative charges (-7, -6, and -6, respectively) but contain a varying number of positively charged residues  
342 (2, 4 and 0, respectively) (Fig 2). As previously shown (Bhopatkar et al., 2020), microscopic  
343 investigations of GRN-3 incubated with PrLD in both redox states showed LSPS (saffron box) while  
344 GRN-5 showed LLPS (green box) under both redox conditions (Fig 4a and b). FRAP confirmed the  
345 observations with a rapid recovery for GRN-5 (liquid) and attenuated recovery for GRN-3 (solid) (Fig 4a  
346 and b). On the other hand, GRN-2 showed LLPS in the oxidized state and LSPS in the reduced state (Fig  
347 4c). This suggests that the number of positive charges in GRN-2 is enough to mitigate LLPS in the

348 reduced state but not enough to attenuate LLPS and promote LSPS in the oxidized state. We conjectured  
 349 that while negative charges on the GRNs promote LLPS, the positively charged residues tend to shift the  
 350 equilibrium towards LSPS and solid aggregates. To further substantiate the role of positive charges, a  
 351 construct was generated in which the two positive charges were mutated to glutamate (negatively  
 352 charged) residue to generate GRN-2 (+/-) mutant that was devoid of any positive charges (net - 9 charge)  
 353 similar to GRN-5. If our hypothesis was correct, abrogation of all positively charged residues would  
 354 promote LLPS in both oxidized and reduced states identical to GRN-5. Co-incubation of GRN-2 (+/-) and  
 355 PrLD did show formation of liquid droplets in both fully oxidized and reduced conditions (Fig 4d),  
 356 further cementing our hypothesis that negative charges drive LLPS. To further illustrate this, GRN-7,  
 357 which has the same number of acidic (-6) residues as the other GRNs but has high number of basic  
 358 residues (+8), with an overall positive charge (+2), was co-incubated with PrLD (Fig S5a). Based on the  
 359 on the inferences drawn thus far, such enrichment of positively charged residues will drive LSPS of  
 360 PrLD, which was confirmed by the presence of solid aggregates on the co-incubated sample monitored  
 361 for 36 h (Fig S5c). Unfortunately, a deeper investigation on this protein was precluded by the difficulties  
 362 in obtaining a pure protein that was prone to substantial proteolytic degradation over time (data not  
 363 shown). Lastly, we evaluated the droplets formed by these proteins with PrLD (Fig S8). The droplet area  
 364 ( $\mu\text{m}^2$ ) of GRN-2 with PrLD shows a normal distribution centered at  $\sim 25 \mu\text{m}^2$  (Fig S8, gray), which is  
 365 similar to that observed for GRN-2(+/-) with PrLD (Fig S8, red). On the other hand, droplets formed in  
 366 the reaction of rGRN-2(+/-) with PrLD shows noticeable reduction in droplet areas with a normal  
 367 distribution centered at  $\sim 10 \mu\text{m}^2$ , suggesting an diminished ability of the reduced form to undergo LLPS.




368  
 369 **Figure 4. Phase transitions of GRNs and specific mutants.** a-d) Sequence of GRN-3, GRN-5, GRN-2  
 370 and GRN-2(+/-) annotated with negative and positive charges present and the net charges on the protein at  
 371 neutral pH (top of each panel). Individual samples are generated by mixing 40  $\mu\text{M}$  of the respective GRN

372 with 20  $\mu\text{M}$  PrLD, along with 1% (molar) fluorophore-labeled proteins (GRNs are labeled with HiLyte-  
 373 405 and PrLD with HiLyte 647) buffered in 20 mM MES, pH 6.0. Samples were visualized by fluorescence  
 374 microscope and their internal dynamics were analyzed by FRAP. Individual micrographs are highlighted  
 375 with a green border for LLPT and a saffron border for LSPT. The fluorescence recovery curves for this preprint  
 376 normalized based on pre-bleaching fluorescence intensities. Scale bar represents 10  $\mu\text{m}$ .

### 377 The redox state of cysteines in GRNs further tunes phase behavior of PrLD coacervates.

378 It is now clear that the complex coacervation of GRN and PrLD is driven predominantly by  
 379 electrostatic interactions; while negative charges drive LLPS the increase in the number of positive  
 380 charges shift the equilibrium towards LSPS. However, what role does the oxidation state of thiols play in  
 381 this process remained unclear. Therefore, to understand their effect, microscopic analysis was performed  
 382 on the co-incubations of GRN-2 and PrLD as a function of a reducing agent (Fig 4). To mimic local redox  
 383 fluxes within the cellular cytoplasm (López-Mirabal & Winther, 2008), the reactions containing 40  $\mu\text{M}$   
 384 GRN-2 and 20  $\mu\text{M}$  PrLD with increasing concentrations (50-600  $\mu\text{M}$ ) of the reducing agent tris(2-  
 385 carboxyethyl)phosphine (TCEP) were probed using fluorescence microscopy (Fig 4a). The TCEP  
 386 concentrations used generate partially reduced (50-300  $\mu\text{M}$ ) to completely reduced (600  $\mu\text{M}$ ) thiols in  
 387 GRN-2. In the absence of the reducing agent, GRN-2, as expected, underwent LLPS with PrLD forming  
 388 liquid droplets that undergo fusion and coalescence as observed previously (0  $\mu\text{M}$  TCEP; Fig 5a). To  
 389 ascertain the droplets' fluid-like properties, their internal dynamics were probed by FRAP which showed  
 390 a rapid recovery for PrLD reiterating an archetypal fluidic characteristic of the droplets (red curve, 0  $\mu\text{M}$   
 391 TCEP; Fig 5a). For reasons not clear at this time, attenuated mobility for the colocalized GRN-2 within  
 392 the liquid droplets was observed as seen in its recovery curve, (blue curve, 0  $\mu\text{M}$  TCEP; Fig 5a).



393  
 394 **Figure 5. Redox state of GRN-2 fine tunes the phase transitions with PrLD.** a) Reactions containing 20  
 395  $\mu\text{M}$  PrLD with 40  $\mu\text{M}$  GRN-2 were initiated separately with increasing TCEP concentrations (50-600  $\mu\text{M}$ )  
 396 buffered in 20 mM MES, pH 6.0. Samples were visualized by fluorescence microscopy and probed with  
 397 FRAP. b) Individual recovery rates of PrLD (red) and GRN-2 (blue) in the reactions of a) obtained using  
 398 the initial rate method (detailed in Materials and Methods). c) Distributions of droplet area ( $\mu\text{m}^2$ ) observed  
 399 within the micrographs of reactions in (a). The droplet area distributions were extracted using ImageJ where  
 400 a total of 100 droplets was considered for each sample and Normal distribution are plotted (detailed in  
 401 Materials and Methods). d) Schematic depicting the GRN-2(C/A) mutant (cysteines replaced with alanines;

402 purple vertical bars). The micrographs represent reactions of 20  $\mu\text{M}$  PrLD with 40  $\mu\text{M}$  GRN-2(C/A)  
403 buffered in 20 mM MES, pH 6.0 along with the FRAP analysis. e-f) Micrographs of mixtures containing  
404 40  $\mu\text{M}$  alkylated-GRN-2 (e; 2-free thiols alkylated, f; 12-free thiols alkylated) generated using  
405 iodoacetamide, with 20  $\mu\text{M}$  PrLD along with the FRAP analysis. For visualization using fluorescence  
406 microscopy, all samples contained 1% fluorophore-labeled proteins (GRN-2, GRN-2(C/A), and alkylated  
407 forms were labeled with HiLyte-405 while PrLD was labeled with HiLyte-647). All reactions were initiated  
408 and imaged at room temperature. Scale bar represents 20  $\mu\text{m}$ .


409 In the presence of 50  $\mu\text{M}$  TCEP (partially reducing conditions), the magnitude of droplet formation  
410 was dampened and structures with an altered morphology alongside the spherical droplets were visible  
411 (50  $\mu\text{M}$  TCEP; Fig 5a). Increasing concentrations of TCEP (150-600  $\mu\text{M}$ ) showed smaller droplets and a  
412 progressive decrease in fluorescence recovery rates for PrLD (Fig 5a and 5b). The rate constant ( $k$ )  
413 deduced by an initial rate method from FRAP data showed a first-order kinetics for PrLD, while GRN-2  
414 showed a diminished rate of recovery in fully oxidized and partially reduced (50  $\mu\text{M}$  TCEP) conditions  
415 (Fig 5b). In fully reducing conditions, the mixture of rGRN-2 and PrLD underwent LSPS, as observed  
416 previously (Figs 3 and 4) generating solid, fibril-like aggregates and was devoid of any droplets, as  
417 confirmed via microscopy and FRAP data (600  $\mu\text{M}$  TCEP; Fig 5a). The use of other reducing agents such  
418 as dithiothreitol (DTT) and glutathione (GSH) also showed similar results (Fig S6). Furthermore, analyses  
419 of droplet size as a function of the reducing agent provided some interesting insights (Fig 5c). The droplet  
420 size distributions, in terms of the surface area, were clubbed into two categories of small (area < 25  $\mu\text{m}^2$ )  
421 and large droplets (25 < area < 250  $\mu\text{m}^2$ ). The coacervates in fully oxidized conditions showed a wide  
422 distribution of droplet sizes. The surface areas of small droplets were centered at  $\sim 10 \mu\text{m}^2$ , with an  
423 average droplet size of 8.2  $\mu\text{m}^2$  (yellow; Fig 5c). In addition, a notable number of droplets larger than 25  
424  $\mu\text{m}^2$  were also observed in the sample with an average surface area of  $\sim 60\text{-}70 \mu\text{m}^2$  (yellow; Fig 5c).  
425 Increasing TCEP concentrations (50-600  $\mu\text{M}$ ) revealed a discernible shift towards smaller droplet  
426 distributions with average surface areas of 4.35, 2.89 and 2.65  $\mu\text{m}^2$  for 50, 150, and 300  $\mu\text{M}$  TCEP  
427 concentrations, respectively (Fig 5c). We attribute this behavior to the reduction in surface tension  
428 introduced by way of thiols solvation or hydrogen bonding interactions.

429 These results bring out two important points; the first is that the modulation of phase transitions by  
430 redox flux is not abrupt but requires full reduction of cysteines to shift the droplets (LLPS) to insoluble  
431 aggregates (LSPS). The second is that the cysteine thiols seem to shift the equilibrium from the liquid to  
432 the solid phase possibly indulging in hydrogen bonding interactions with bulk water (solvation) and with  
433 PrLD. If this is the case, we argued that abrogation of cysteines (and therefore, thiols) will render GRN-2  
434 to behave as in fully oxidizing conditions. To test this hypothesis, all 12 cysteines in GRN-2 were  
435 mutated to alanines to generate GRN-2(C/A) mutant. Indeed, the co-incubation of PrLD with GRN-  
436 2(C/A) immediately showed LLPS to form liquid droplets with high rates of fluorescence recovery  
437 confirming a fluid-like character (Fig 5d). The similarity in the behavior of GRN-2(C/A) and GRN-2 is  
438 also apparent from the droplet size observed (Fig S8). The droplet areas of the mutant form (Fig S8,  
439 green) have a similar distribution to that of the wild type (Fig S8, gray), with an average value of  $\sim 25$   
440  $\mu\text{m}^2$ . On the contrary, when all the free thiols in the fully reduced form of rGRN-2 were alkylated and  
441 capped with acetamide (GRN-12alk), a moiety, which is expected both to be solvated by bulk water and  
442 engage in hydrogen bonding interactions with PrLD perhaps to a greater extent than thiols, the  
443 coacervates formed solid like structures with attenuated internal mobility as revealed by FRAP (Fig 5e).  
444 Similarly, acetamide alkylation of two free thiols present in the fully oxidized samples (Fig S4), which  
445 mimics partially reducing conditions also showed no change from those incubated in the presence of 50

446  $\mu\text{M}$  TECP (Fig 5f). Together, the data bring to light the role of cysteine in phase transitions of PrLD and  
447 GRNs, which is one of modulatory nature, fine-tuning the transitions only GRN-2, which happens to fall  
448 in category of partially counter-balanced positive and negative charges. As observed before (Bhopatkar et  
449 al., 2020), GRNs 3 and 5 showed no effect on respective phase transitions due to the extremity of the  
450 electrostatics in their respective cases.

### 451 GRN-2 delays but induces ThT-positive aggregates of TDP-43 PrLD in oxidized or reduced states.

452 We have previously shown the concentration-dependent LLPS of PrLD by GRN-5 or LSPS by GRN-  
453 3 are accompanied by a delayed emergence of thioflavin-T (ThT) fluorescence (Bhopatkar et al., 2020),  
454 which is a reporter of amyloid-like aggregates (Xue, Lin, Chang, & Guo). To see whether GRN-2 in both  
455 redox forms induces ThT-positive PrLD aggregates, the co-incubations of increasing concentrations of  
456 GRN-2 or rGRN-2 and PrLD were monitored for 24 hours in the presence of ThT (Fig 6a). All reactions  
457 showed slightly elevated ThT levels at the beginning (0h; Fig 6a) but failed to show sigmoidal increase of  
458 ThT fluorescence as observed for the control PrLD (Fig 6a). This observation was similar to that observed  
459 previously with GRN-3 and GRN-5 (Bhopatkar et al., 2020). Microscopic investigations of the reactions  
460 with GRN-2 showed the formation of liquid droplets in all stoichiometric equivalence immediately after  
461 incubation (0h; Fig 6b). After 24h, the droplets continue to be present although a few of them showed  
462 morphological changes possibly gelation (24h; Fig 6b). To probe this possibility, we performed FRAP  
463 studies on the structures after a 24h period. Compared to the fluorescence recovery shown by the liquid  
464 droplets of 40  $\mu\text{M}$  GRN-2 with 20  $\mu\text{M}$  PrLD (Fig 6b, FRAP, 0 h; red), the distorted droplets visible in  
465 samples of all stoichiometric reactions, show attenuation in their recovery kinetics (Fig 6b, FRAP, 24 h;  
466 brown) confirming the ‘gelation’ of the liquid-like droplets observed initially. Also, this attenuation  
467 shows a positive correlation to the concentration of GRN-2 present in the mixture. In fully reducing  
468 conditions, incubations of rGRN-2 with PrLD showed an instantaneous formation of insoluble aggregates  
469 that persisted after 24 h (Fig 6c). However, after > 60 hours of incubation, all the reactions with rGRN-2  
470 and those with GRN-2 in lower stoichiometric equivalence showed increases in ThT intensities towards  
471 amyloid like materials (Fig S6).




472

473 **Figure 6. Amyloid formation of PrLD in presence of GRN-2.** a) The amyloid formation of 20  $\mu\text{M}$  TDP-  
474 43 PrLD alone ( $\bullet$ ) or in presence of varying concentrations (2-40  $\mu\text{M}$ ) of GRN-2 or rGRN-2, buffered in  
475 20 mM MES, pH 6.0, monitored using 15  $\mu\text{M}$  ThT for a period of 24 h at 37  $^{\circ}\text{C}$  under quiescent conditions.  
476 b-c) Micrographs of reactions in (a) visualized using brightfield and fluorescence microscope with 1%  
477 fluorophore-labeled PrLD (HiLyte-647) imaged at 0 h and after an incubation of 24 h. b) The droplets  
478 observed initially upon mixing GRN-2 with 20  $\mu\text{M}$  PrLD were subjected to FRAP analysis immediately  
479 and after 24 h (0 and 24 h, red and brown curves, respectively). c) Microscopic visualization of PrLD in the

480 presence of varying concentrations of rGRN-2 (2-40  $\mu\text{M}$ ) shows the formation of solid deposits at 0 h and  
 481 24 h. Scale bar represents 10  $\mu\text{m}$ .

482 **RNA competes and displaces GRN-2 from PrLD coacervates.**

483 Under cellular stress conditions, PrLD transfected in SH-SY5Y cells is either found in SGs along  
 484 with TIA1 or colocalized with GRNs in the cytoplasm but colocalization of all three was not observed  
 485 (Fig S1). We conjectured that it is due to potential competition between GRNs and RNA, in which the  
 486 latter displaces the former in SGs. To test this, ternary interactions between RNA, GRN-2, and PrLD were  
 487 investigated in vitro (Fig 7). PrLD (20  $\mu\text{M}$ ) was co-incubated with three GRN-2 concentrations of 10, 20  
 488 and 40  $\mu\text{M}$ , and each co-incubated sample was investigated with the addition of increasing RNA (poly A)  
 489 concentrations (0-150  $\mu\text{g}/\text{mL}$ ). The positive control, PrLD, and RNA showed prototypical turbidity  
 490 increase increasing RNA concentrations that saturated about 50  $\mu\text{g}/\text{mL}$  and showed a slight drop in  
 491 turbidity at 150  $\mu\text{g}/\text{mL}$  (●; Fig 7a). Increasing RNA concentrations in PrLD-GRN-2 co-incubations also  
 492 showed similar trends but with higher initial turbidity values (●, ●, and ●; Fig 7a). Irrespective of the  
 493 concentration of GRN-2 in the mixture, the eventual turbidity values of all samples converge to that  
 494 shown by PrLD with 150  $\mu\text{g}/\text{mL}$  RNA. This hints at the similar compositional make-up of the final  
 495 condensates which is insensitive to GRN-2 concentration in the presence of high RNA concentration (Fig  
 496 7a). To probe the internal dynamics of these interactions, we used fluorescence microscopy with  
 497 fluorophore-labeled proteins and repeated the experimental setup. Co-incubations of varying  
 498 concentrations of GRN-2 with PrLD, in the absence of RNA, showed droplet formation as expected (0  
 499 RNA; Fig 7b-e). The addition of increasing amount of RNA to 10  $\mu\text{M}$  GRN-2 incubations showed a  
 500 steady displacement of GRN-2 (blue) from within the droplet from  $\sim 50$ -75  $\mu\text{g}/\text{mL}$ , while PrLD (red)  
 501 remained largely unaffected (Fig 7c). Between 100 and 150  $\mu\text{g}/\text{mL}$  of RNA, GRN-2 has been completely  
 502 displaced from the droplet (Fig 7c). Interestingly, the displacement and substitution of GRN-2 did not  
 503 occur concertedly but involved the formation of heterologous coexisting multiphase condensates with  
 504 coacervates of PrLD-RNA engulfing PrLD-GRN-2 as deduced by the fluorescence intensity plots (Fig  
 505 7c).



507 **Figure 7. Ternary interactions between GRN-2, PrLD and RNA.** a) Turbidity plots obtained by titrating  
 508 20  $\mu\text{M}$  PrLD with increasing RNA concentration (25-150  $\mu\text{g}/\text{mL}$ ) in the presence (●; 10  $\mu\text{M}$ , ●; 20  $\mu\text{M}$   
 509 or ●; 40  $\mu\text{M}$  GRN-2) or the absence of GRN-2 (●). b-e) Confocal micrographs depicting selective droplets  
 510 observed in reactions from (a). Displacement of GRN-2 upon titration with RNA was observed by the

511 fluorescence intensity profiles of the respective fluorophore-labeled proteins (GRN-2 with HiLyte-405 and  
512 PrLD with HiLyte-647) was extracted across the width of the droplets using ImageJ (detailed in Materials  
513 and Methods). f) Microscopic visualization of complex coacervates of 20  $\mu\text{M}$  PrLD with varying RNA  
514 concentrations (25-75  $\mu\text{g}/\text{mL}$ ) generated initially were titrated with 40  $\mu\text{M}$  rGRN-2. All reactions were  
515 initiated and imaged at room temperature. Unless specified, scale bar represents 10  $\mu\text{m}$ .

516 A similar behavior was observed with increased GRN-2 concentrations (20 and 40  $\mu\text{M}$ ) also (Fig 7d-e).  
517 Such co-existing heterotypic condensates have also been observed in ternary complexes involved in  
518 prion-like polypeptide, RNA and arginine-rich polypeptides (Kaur et al., 2021). Similar to Kaur and  
519 colleagues, we observe a ternary system in which RNA-PrLD interactions out compete and dominate  
520 PrLD-GRN-2 interactions by displacing GRN-2. This also suggests that GRN-2 and RNA are mutually  
521 exclusive binding partners for PrLD demixing and LLPS, which in turn explains why GRN-2 are not  
522 observed in SGs. Furthermore, we also examined the effect of rGRN-2 on the condensates of PrLD-RNA  
523 was also examined (Fig 7f). Here, condensates of 20  $\mu\text{M}$  PrLD with varying RNA concentrations (25-75  
524  $\mu\text{g}/\text{mL}$ ) were generated and 40  $\mu\text{M}$  rGRN-2 was added followed by visualization using fluorescence  
525 microscopy. We observed that at a low RNA concentration (25  $\mu\text{g}/\text{mL}$ ), rGRN-2 is able to interact with  
526 unengaged PrLD within the mixture and drive its LSPS (Fig 7f, +25 RNA) similar to that observed in the  
527 absence of any RNA (Fig 7f, 0 RNA). In the condensates of PrLD-RNA generated with higher RNA  
528 concentrations (50-75  $\mu\text{g}/\text{mL}$ ), the external addition of rGRN-2 leads to minimal or no LSPS with the  
529 sustenance of RNA-PrLD condensates, as seen in the micrographs (Fig 7f, +50 and +75 RNA). This result  
530 reiterates the dominance of PrLD-RNA interactions over PrLD-GRN-2/rGRN-2 interactions and further  
531 supports the idea of displacement of GRN-2 from SGs in cells by RNA.

532


## 533 DISCUSSION

534 The precise role of GRNs in the pathophysiology of neurodegenerative disorders has remained an  
535 open question. In general, under what conditions and cellular cues are they generated from their precursor  
536 PGRN, and what role do they play in cellular functions and dysfunction has been a point of debate  
537 (Bateman, Belcourt, Bennett, Lazure, & Solomon, 1990; Bateman & Bennett, 1998; Holler et al., 2017;  
538 Horinokita et al., 2019; Kao, McKay, Singh, Brunet, & Huang, 2017; Root et al., 2021). What we do  
539 know is that PGRN secreted from microglia and astrocytes are transported into neuronal lysosomes by a  
540 sortilin-mediated pathway (Hu et al., 2010; Kao et al., 2017) and that the proteolytic processing generates  
541 GRNs within the lysosomes (Holler et al., 2017; Chris W. Lee et al., 2017) but what functional roles they  
542 play in lysosomes remain uncertain. PGRN also undergoes proteolytic cleavage extracellularly during  
543 inflammation (Zhu et al., 2002), and the fate of extracellular GRNs on neuronal functions also remains  
544 completely unknown. Here we investigated the cellular localization and interaction of extracellular GRNs  
545 (GRN-2, -3 and -5) with TDP-43 by treating them onto SHSY5Y neuroblastoma cells that transiently  
546 express TDP-43 PrLD. These studies along with in vitro biophysical investigations on the interactions  
547 between the two proteins in greater detail have brought out some unexpected properties of GRNs and  
548 PrLD that unravel GRNs' potential role in FTLD and related pathologies.

549 To understand the fate of extracellular GRNs on neurons, we labeled GRNs only with organic  
550 fluorophores (HiLyte) to visualize their uptake but were devoid of any tags that may predispose them for  
551 specific cellular localization. The data indicate that the GRNs are taken up by SH-SY5Y cells to be  
552 localized not only within lysosomes, which is well-known, but in the cytosol also. More importantly,  
553 GRNs colocalize with TDP-43 PrLD in the cytoplasm both under stress and non-stress conditions



554 indicating their potential involvement in FTL and ALS pathologies (Fig 1). Furthermore, under stress  
555 conditions, based on the lack of FRAP recovery and absence of colocalization with the SG marker TIA1  
556 (Fig S1), we could conclude that GRNs fail to partition within the SGs. In addition, we infer that the  
557 cytosolic colocalizations observed are complex cytoplasmic coacervates of PrLD and GRNs.  
558 Interestingly, unlike with PrLD, GRNs failed to colocalize with full-length TDP-43 either in non-stress  
559 conditions or within SGs under stress conditions (Fig S2), illustrating that GRNs may specifically interact  
560 with the pathogenic proteolytic fragments of TDP-43, for which the PrLD constitutes the major part  
561 (Feneberg et al., 2020), further implicating their role in pathology.  
562



563  
564 **Figure 8. Schematic summary of complex coacervation between GRNs and PrLD.** (a) Phase transitions  
565 of PrLD induced by GRNs. (b-g) Phase changes are coarsely controlled by electrostatic interactions (large  
566 knob) while they are finely controlled by the redox state (smaller knob) for some select conditions  
567 discovered in this report.

568 The dynamics of interactions between GRN-2 and PrLD investigated here have furthered our  
569 understanding of the possible mechanisms by which GRNs could modulate intracellular inclusions of  
570 TDP-43. Complex coacervation of TDP-43 with RNA has been known to be an electrostatically driven  
571 process (Babinchak et al., 2020; Lim et al., 2016). In a similar vein, we showed that coacervation with  
572 GRNs is likely driven by net charges on the protein (Bhopatkar et al., 2020). The charge distribution on  
573 GRNs 2, 3 and 5 shows that they are isoelectronic to negative charges, but with respect to positive  
574 charges, GRN-2 with +2 is in the middle between GRNs 3 and 5 (+4 and 0, respectively) (Fig 2). This  
575 facilitated the investigations on GRN-2's interactions with PrLD to draw biophysically meaningful  
576 inferences as GRN-3 and -5 have been shown to display a spectrum of phase transitions upon interacting  
577 with PrLD (Bhopatkar et al., 2020). The results presented here establish that the negative charges are the  
578 main driving forces of LLPS between GRNs and PrLD while the increase in the number of positive  
579 charges shifts the equilibrium towards LSPP (Fig 8a). To a lesser degree, hydrophobic interactions also  
580 seem to contribute possibly via cation -  $\pi$  and  $\pi$  -  $\pi$  interactions but certainly do not seem to drive LLPS.

581 Interestingly, by simply modulating the charges on GRNs, one could seemingly control the dynamics of  
582 phase transitions and complex coacervation with PrLD as summarized in Figure 8b-g. When under the  
583 control of purely negative charges on GRN, PrLD undergoes LLPS to form droplets that are demixed  
584 from the solution (Fig 8b and c). This can be explained based on polyphasic linkage and ligand binding  
585 effect on phase transitions as recently postulated by Ruff and coworkers (Ruff, Dar, & Pappu, 2021).  
586 Based on their work, preferential binding of a ligand (GRN) to the scaffold (PrLD) in dilute or dense  
587 phase can be expressed as;

$$588 \quad C_{dil,L} = C_{dil} \left( \frac{P_{dil}}{P_{den}} \right)$$

589 Where  $C_{dil,L}$  is concentration of the scaffold in the coexisting dilute phase in ligand's presence,  $P_{dil}$  and  
590  $P_{den}$  are binding polynomials that define ligand binding to the scaffold in respective phases. If  $P_{dil} > P_{den}$ ,  
591 i.e., binding of ligand to the scaffold is greater in the dilute phase,  $C_{dil,L} > C_{den}$ , LLPS gets suppressed and  
592 when  $P_{dil} < P_{den}$  LLPS is augmented. Therefore, negative charges potentiate multivalent electrostatic  
593 charges with PrLD to preferentially partition into the dense phase, thus promoting LLPS. Increasing the  
594 number of positive charges to four shifts the equilibrium towards the formation of solid aggregates  
595 possibly by engaging in additional salt-bridge interactions with acidic residues of PrLD, preferably in the  
596 dilute phase (Fig 8d and e). These interactions, we speculate also promote aggregation. Unfortunately, we  
597 do not have experimental evidence for this extreme case (high positive charges and no negative charges),  
598 as such a mutant posed difficulties in recombinant expression (data not shown). However, the results  
599 obtained from GRN-7 (Fig S5), which has a high number of positive charge (+8) serves as a good proxy  
600 and strengthen the validity of the idea that GRNs have modulatory capabilities especially when it is  
601 known that not all GRNs level are the same in cells (T. Zhang et al., 2021).

602 Perhaps the most interesting aspect of this behavior is the role of cysteines and redox control. Our  
603 data indicate that when under compensatory positive and negative charge regimes in GRNs, redox  
604 conditions dictate the phase transitions (Fig 8f and g). Under fully reducing conditions, thiols in cysteines  
605 may participate in a network of hydrogen bonding interactions with Ser and/or Asn residues that are  
606 abundant in PrLD. Both these residues are conducive partners of cysteines as H-bonding donors and  
607 acceptors (Mazmanian, Sargsyan, Grauffel, Dudev, & Lim, 2016) and are abundant in PrLD (together  
608 accounting for ~40% of the sequence). Empirically, it is evident that these additional valences increase  
609 solute-solute interactions that shift the equilibrium out of the liquid-like state towards an aggregated state.  
610 The possibility of such a scenario is supported by the behavior of the alkylated forms of GRN-2 (Fig 5),  
611 where the polar acetamide adducts are capable of engaging in similar interactions. But under oxidizing  
612 conditions, the disulfide bonded cysteines preclude such interactions are abrogated, and therefore  
613 maintain weak and transient interactions that promote LLPS and a demixed state. From this, we surmise  
614 that the positively charged residues and thiols help fine-tune the phase transitions. It is also noteworthy  
615 that not an abrupt, but a continuum of phase changes is observed when traversing between one end of the  
616 redox spectrum to the other (Fig 5), which indicates that even under partially reducing conditions, LLPS  
617 can occur to some degree. Therefore, it seems plausible that GRN-PrLD droplets and aggregates could  
618 co-exist in the cytoplasm which largely presents a reducing environment.

619 The data presented here unambiguously establishes complex coacervation between PrLD and GRNs,  
620 yet, the absence of GRNs in SGs within PrLD or full-length TDP-43 expressing neuroblastoma cells  
621 seems to counter-intuitive at the outset. However, as observed by the ternary interactions between PrLD,  
622 GRN-2 and RNA, the reason for the inability of GRNs to partition into SGs is clear. GRN within the  
623 condensates of PrLD simply gets displaced by a stronger electrostatic ligand, RNA, which abrogates the

624 possibility of the three co-existing within the SGs. Given that SGs also contain many other phase  
625 separating proteins such as TIA1 (Kedersha et al., 2000), G3BP1 (Yang et al., 2020), hnRNPA1 (Guil,  
626 Long, & Cáceres, 2006) etc., the likelihood of GRNs partitioning into SGs is low. Furthermore, it is also  
627 interesting to observe that RNA is able to out-compete GRN-2 in reducing conditions where it forms  
628 insoluble aggregates with PrLD (Fig 7). This, along with the observed colocalization of GRN and PrLD  
629 in non-stress conditions, suggest that SGs mitigate potential toxicity posed by GRN-PrLD inclusions  
630 which eventually transition to amyloids, with an intervening gelled phase.

631 This report brings out the first evidence for the cellular uptake of extracellular GRNs and their  
632 cytoplasmic colocalization with PrLD. The exquisite control and tuning of complex coacervation of PrLD  
633 by GRNs via electrostatics and redox flux present intriguing possibilities by which GRNs can influence  
634 pathology. During acute inflammation, when GRNs are known to be generated in abundance by microglia  
635 and astrocytes (Ahmed, Mackenzie, Hutton, & Dickson, 2007; Baker & Manuelidis, 2003; Malaspina,  
636 Kaushik, & de Belleruche, 2001; Zhu et al., 2002), these pro-inflammatory molecules are taken up by  
637 neurons where they modulate the dynamics of cytotoxic proteolytic fragments of TDP-43. Even with  
638 haploinsufficiency of PGRN, which is a risk factor for FTLD, it can be conjectured that inflammation  
639 could lead to augmented production of GRNs that could compensate for the loss in PGRN (Zhu et al.,  
640 2002). Nevertheless, precisely what cellular consequences do these inclusions and coacervates possess  
641 remain unclear at this time. A few possibilities include mitochondrial, lysosomal, and autophagic  
642 dysfunction. Some of these will be unearthed in the coming years with the establishment of complex  
643 interactions and phase transitions between GRNs and TDP-43 PrLD as described in this report.

644

## 645 **Materials and Methods**

### 646 **Recombinant expression and purification of proteins.**

647 **GRNs.** GRNs (GRN-2, GRN-2(+/-), GRN-2(C/A), GRN-3, and GRN-5) were recombinantly expressed  
648 and purified as previously described, where GRN-3 was expressed in *Escherichia coli* SHuffle cells (New  
649 England Biolabs) while other GRNs were expressed in Origami 2 DE3 cells (Invitrogen) (Bhopatkar et  
650 al., 2020). Briefly, GRNs were expressed as fusion constructs containing an N-terminal thioredoxin-A,  
651 and His<sub>6</sub> tag with an intervening thrombin cleavage site. The fusion constructs were purified using  
652 immobilized-nickel affinity chromatography. The purified construct was cleaved using restriction grade  
653 bovine thrombin (BioPharm Laboratories) at 3 units/1 mg of protein for 24 h at room temperature to  
654 separate the fused tags. The sample was fractionated using semipreparative Jupiter 5  $\mu$ m-10 x 250 mm  
655 C18 reverse-phase HPLC column (Phenomenex) using a gradient elution of 60%–80% acetonitrile  
656 containing 0.1% TFA. Fractionated protein was lyophilized and stored at -20°C. For the generation of 2-  
657 alkylated GRN-2 i.e. GRN-2 with two-free thiols that are alkylated, the protein was incubated with 10  
658 molar excess of iodoacetamide post-thrombin cleavage for a period of 24 h at room temperature. Protein  
659 was then fractionated using reverse-phase HPLC as before. For the generation of 12-alkylated GRN-2 i.e.  
660 GRN-2 with all twelve thiols alkylated, the protein was incubated with 12x molar excess of TCEP post-  
661 thrombin cleavage for a period of 12 h at room temperature followed by incubation with 10 molar excess  
662 of iodoacetamide for 24 h at room temperature. Protein was then fractionated using reverse-phase HPLC  
663 as before. The purity of protein was confirmed using matrix assisted laser desorption-ionization time-of-  
664 flight mass spectroscopy (MALDI-ToF MS)

665 **TDP-43 PrLD.** PrLD was expressed and purified as described previously (Bhopatkar et al., 2020). The  
666 plasmid for TDP-43 PrLD was a gift from Dr. Nicolas Fawzi at Brown University (Addgene plasmid  
667 98669, RRID: Addgene 98669). Briefly, the protein was expressed as a fusion construct with an N-

668 terminal His<sub>6</sub> tag followed by tobacco etch virus (TEV) protease cleavage site in *E. coli* BL21 DE3 Star  
669 cells (Invitrogen). The fusion construct was purified using immobilized-nickel affinity chromatography.  
670 Purified protein was concentrated using Amicon Ultra-Centrifugal units (Millipore) and flash frozen for  
671 storage at -80°C or used immediately for experiments.

### 672 **Preparation of proteins and RNA**

673 **GRNs.** Lyophilized protein was resuspended in required buffer (20 mM MES, pH 6.0 or 20 mM  
674 ammonium formate, pH 4.5) and the concentration was estimated spectrophotometrically at 280 nm with  
675 extinction coefficients of 6250 M<sup>-1</sup> cm<sup>-1</sup> for GRN-2, GRN-2(+/-) and GRN-3, 5500 M<sup>-1</sup> cm<sup>-1</sup> for GRN-  
676 2(C/A), 7740 M<sup>-1</sup> cm<sup>-1</sup> for GRN-5 at 280 nm. The number of free thiols within GRNs was estimated using  
677 Ellman's assay and by alkylation with iodoacetamide, as described previously (Ghag et al., 2017). The  
678 reduced forms of GRNs were generated by incubating the freshly purified proteins with 12x molar excess  
679 of tris(2-carboxyethyl)phosphine (TCEP) at room temperature for 2-4 h or at 4°C for ~12 h. Fluorescent  
680 labeling of GRNs was performed using HiLyte™ Fluor 405 succinimidyl ester (Anaspec) or HiLyte™  
681 Fluor 647 succinimidyl ester for FRAP studies on GRNs. Proteins were incubated with 3 molar excess of  
682 dyes at 4°C for ~12 h and excess dye was excluded using clarion MINI Spin Columns, Desalt S-25  
683 (Sorbent Technologies Inc).

684 **PrLD.** Before the experiments, the protein was buffer-exchanged into 20 mM MES, pH 6.0 or 20 mM  
685 ammonium formate, pH 4.5, using PD SpinTrap G-25 desalting columns (Cytiva) and the concentration  
686 was estimated using an extinction coefficient of 19480 M<sup>-1</sup> cm<sup>-1</sup> at 280 nm. Fluorescent labeling of PrLD  
687 was performed using HiLyte™ Fluor 647 succinimidyl ester (Anaspec) using a similar protocol as  
688 described above for GRNs.

689 **RNA.** Lyophilized poly-A (Sigma Aldrich) was resuspended in deionized, sterilized water at a  
690 concentration of 1 mg/mL. The concentration of the stock was estimated by considering a value of 1  
691 absorbance unit to correspond to 40 µg of RNA. The prepared stock was flash frozen and stored at -80°C.  
692 Aliquots of prepared stock were thawed and used immediately for experiments.

693

### 694 **Cell growth, transfection and colocalization analysis**

695 SH-SY5Y neuroblastoma cells (ATCC, Manassas, VA) were grown in DMEM:F12 (1:1) media  
696 containing 10% FBS (Gibco, Thermo Scientific) and were maintained in humidified condition at 37 °C  
697 with 5.5% CO<sub>2</sub>. Cells were seeded 24 hours before transfection. Cells were transfected with PrLD-  
698 SBFP2 or wtTDP43tdTomato plasmid using the TransIT-X2® dynamic delivery system, Mirius (1:3) in  
699 Opti-MEM media (Thermo scientific). Cell confluency was allowed to reach 70-80% prior to  
700 transfection. After 24 h, cells were gently washed for two times with fresh media and 500 nM of  
701 fluorescently labeled recombinant GRNs were added. Cells were incubated with GRN-containing media  
702 for 24 hours. Following this, media was replaced with GRN-devoid media and cells were incubated for a  
703 further 1 h. For inducing stress, sodium arsenite was added at a final concentration of 0.5 mM and  
704 incubated for 30 minutes. Cells were stained with nuclear (NucSpot® Live 650, Biotium) or lysosomal  
705 (Lysoview™ 650, Biotium) markers prior to imaging at 40X magnification using Leica STELLARIS-  
706 DMI8 microscope. For colocalization analysis of GRNs and PrLD, the respective channels for PrLD and  
707 GRNs were converted to 16-bit grayscale format and region of interest was selected. Images were  
708 processed using Coloc2 parameter in FIJI imageJ software using Costes threshold regression, and  
709 Manders' tM1 values were reported. All the confocal images were processed using Adobe illustrator and  
710 data were processed using OriginPro 8.5 software.

711

712

## 713 **Immunofluorescence**

714 For immunofluorescence experiment, cells were plated in a 12 well plate 24 h prior to transfection with  
715 PrLD-SBFP2 as described above. After incubating with fluorophore labeled-GRNs for 24 h, media was  
716 replaced, and experiments were carried out in both stress and non-stress conditions. For induction of  
717 stress, 0.5 mM sodium arsenite was added to the media and incubated for 30 minutes followed by  
718 washing with 1x PBS. Cells were fixed in 4% paraformaldehyde for 20 minutes and washed twice with  
719 1x PBS. These were further permeabilized with 0.2% Triton X-100 in 1x PBS for 20 minutes. Cells were  
720 washed and blocked using 3% BSA for 2 h. Cells were incubated with anti-TIA1 primary antibodies (Cell  
721 Signaling Technology, TIAR XP® Rabbit mAb #8509) and anti-rabbit secondary antibodies (Cell  
722 Signaling Technology, Alexa Flour® 488 conjugate #4412) and imaged following the addition of anti-  
723 fade mounting media at 40X magnification on Leica STELLARIS-DMI8 microscope.

## 724 **DIC Microscopy and FRAP analysis**

725 DIC and fluorescence microscopy images were acquired on Leica STELLARIS-DMI8 microscope. The  
726 assays were performed in an optical bottom 96 well-plate (Thermo) and were covered with an optically  
727 clear sealing tape (Nunc, Thermo Scientific) to prevent evaporation. The reactions were initiated at room  
728 temperature and were visualized within 10-15 mins of mixing. Brightfield and fluorescence images were  
729 acquired at a magnification of 40x or 63x with an oil immersion objective. For microscopically  
730 monitoring the ternary interactions between GRN-2, PrLD and RNA; we initially generated heterotypic  
731 condensates of GRN-2 and PrLD, followed by titration with desired volumes of the RNA stock. Images  
732 were acquired after an equilibration time of ~10-15 mins after each titration. The RNA stocks were  
733 prepared at a high initial concentration to minimize dilution effects upon titration. For fluorescence  
734 imaging and FRAP studies, samples were prepared by mixing the required concentration of proteins in an  
735 optical-bottom 96 well plate in the presence of 1% fluorophore labelled proteins. For FRAP studies,  
736 fluorescence intensities were acquired pre- (~2 seconds) and post-bleach (~30 seconds) at an interval of  
737 68  $\mu$ s. Bleaching period was varied from 10-20 seconds with a laser intensity of 100% while the laser  
738 intensity for imaging was set at 2-10%. The fluorescence recovery data was processed using Leica LasX  
739 program and Origin 8.5 graphing software. The recovery curves of individual samples were normalized  
740 with respect to the pre-bleach fluorescence intensities. To discern the rate constants of recovery kinetics  
741 post-bleach the initial-rate method was utilized (Buell et al., 2014; Dean, Rana, Campbell, Ghosh, &  
742 Rangachari, 2018). Briefly, period of fluorescence recovery 1 second post-bleach was evaluated via a  
743 linear fit with the slope of the line providing a rate constant,  $k$  ( $s^{-1}$ ). Rate constants were obtained by  
744 evaluating three FRAP recovery curves for each sample. For time-course experiments, FRAP analysis  
745 was performed on samples at initial time (0 h) and after incubation of 24 h at 37°C under quiescent  
746 conditions. A noteworthy point is that we observed significant photobleaching of HiLyte-405 when  
747 performing FRAP analysis of GRNs labeled with the fluorophore precluding the use of this dye in this  
748 study. To obtain this data, we then cross-labeled GRNs with HiLyte-647 (for performing FRAP studies)  
749 and PrLD with HiLyte-405 (only for visualization).

## 750 **Post imaging analysis**

751 ***Droplet area distribution.*** Area of the droplets formed within various samples was ascertained using the  
752 ImageJ program. Briefly, the fluorescence images acquired for the respective samples were subjected to  
753 color thresholding at default values in the program. Area of droplets within the threshold images were  
754 then extracted using the included particle analyzer tool of the program. A lower limit of either 50 or 200  
755 ( $\text{pixel}^2$ ) (depending on image magnification) was placed on area of particles to be analyzed so as to  
756 exclude detection of small artifacts. Areas obtained in  $\text{pixel}^2$  were converted into  $\mu\text{m}^2$  by considering the

757 scale-bar. The obtained data was then plot as a histogram overlaid with normal distribution curve using  
758 Origin 8.5. A set of 100 droplets were enumerated from at least two different fields for each sample  
759 **Fluorescence intensity profiles.** To qualitatively ascertain the displacement of GRN-2 from condensates  
760 upon titration with RNA, we determined the fluorescence intensity profiles of the fluorophore labeled  
761 proteins from the images of the respective samples using the ImageJ program. Intensity profiles were  
762 obtained by mapping a line segment across the width of a droplet and extracting the intensities of the  
763 fluorophores (HiLyte 405 for GRN-2 and HiLyte 647 for PrLD) using the plot-profile tool. The plot-  
764 profile tool provides intensity values within an arbitrary window of 0-80 units, with highly fluorescent  
765 samples being cut-off at the upper limit. The fluorophore intensities obtained in a pixel scale were then  
766 converted into  $\mu\text{m}$  using the scale-bar. The fluorescence intensity profile was extracted from individual  
767 droplets for each sample but are representative of the entire field.

768

### 769 **Turbidimetric assays**

770 Turbidity measurements were performed on a BioTek Synergy H1 microplate reader. Reactions were  
771 initiated and allowed to equilibrate at room temperature for 5-10 mins before each measurement. For  
772 titration experiments with GRNs, NaCl, or RNA, stocks were prepared at high concentrations to minimize  
773 dilution of samples. For establishment of phase diagrams, a boundary value of 0.140 OD<sub>600</sub> was set and  
774 readings above it were considered to undergo phase transition. Temperature dependent phase diagram was  
775 established by equilibrating samples at respective temperature (4°C, room temperature) for 15 mins, while  
776 temperatures above 30°C were achieved using the internal temperature control capability of the plate  
777 reader. Data processing was performed on Origin 8.5.

778

### 779 **Aggregation assay**

780 To monitor the amyloid-formation of PrLD in presence of GRN-2 or rGRN-2, thioflavin-T (ThT)  
781 fluorescence assays were performed on BioTek Synergy H1 microplate reader. The aggregation of PrLD  
782 was monitored in the presence of different molar concentrations of GRN-2 or rGRN-2 in separate  
783 reactions in the presence of 15  $\mu\text{M}$  ThT dye. The reactions were monitored for a period of 24 h under  
784 quiescent conditions at 37°C.

785

### 786 **MALDI-ToF MS**

787 For confirming the purity and for characterization of proteins used, MALDI-ToF MS spectroscopy was  
788 performed on a Bruker Daltonics Microflex LT/SH TOF-MS system. Prepared samples were spotted onto  
789 a Bruker MSP 96 MicroScout Target microchip with a 1:1 ratio of sample:sinapinic acid matrix in  
790 saturated acetonitrile and water. Instrument calibration was performed using Bruker Protein Calibration  
791 Standard I (Bruker Daltonics). Alkylation assays of GRNs using iodoacetamide were performed as  
792 described (Bhopatkar & Rangachari, 2021).

793

### 794 **In-silico analysis and figure preparation**

795 Redox-dependent disorder scores for individual proteins were obtained using IUPred2A platform (Erdős  
796 & Dosztányi, 2020). Specifically, the FASTA sequence of each protein was evaluated by coupling the  
797 IUPred2 long disorder algorithm with a Redox-state tool (Mészáros et al., 2018). The obtained figures  
798 were processed using the Adobe Illustrator CC suite and Affinity Designer®.

799

800

## 801 **Acknowledgements**

802 The authors would like to thank the following agencies for financial support: National Institute of Aging  
803 (1R56AG062292-01) and the National Science Foundation (NSF CBET 1802793) to VR. The authors  
804 also thank the National Center for Research Resources (5P20RR01647-11) and the National Institute of  
805 General Medical Sciences (8 P20 GM103476-11) from the National Institutes of Health for funding  
806 through INBRE for the use of their core facilities.  
807

## 808 **Competing interests statement**

809 The authors declare that they have no financial or non-financial interests.  
810

## 811 **References**

- 812 Ahmed, Z., Mackenzie, I. R., Hutton, M. L., & Dickson, D. W. (2007). Progranulin in frontotemporal  
813 lobar degeneration and neuroinflammation. *J Neuroinflammation*, *4*, 7. doi:10.1186/1742-2094-4-  
814 7
- 815 Arrant, A. E., Onyilo, V. C., Unger, D. E., & Roberson, E. D. (2018). Progranulin Gene Therapy  
816 Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal  
817 Dementia and Neuronal Ceroid Lipofuscinosis. *The Journal of Neuroscience*, *38*(9), 2341.  
818 doi:10.1523/JNEUROSCI.3081-17.2018
- 819 Babinchak, W. M., Dumm, B. K., Venus, S., Boyko, S., Putnam, A. A., Jankowsky, E., & Surewicz, W.  
820 K. (2020). Small molecules as potent biphasic modulators of protein liquid-liquid phase  
821 separation. *Nature Communications*, *11*(1), 5574. doi:10.1038/s41467-020-19211-z
- 822 Baker, C. A., & Manuelidis, L. (2003). Unique inflammatory RNA profiles of microglia in Creutzfeldt-  
823 Jakob disease. *Proc Natl Acad Sci U S A*, *100*(2), 675-679. doi:10.1073/pnas.0237313100
- 824 Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. *Lancet*, *386*(10004), 1672-1682.  
825 doi:10.1016/s0140-6736(15)00461-4
- 826 Bateman, A., Belcourt, D., Bennett, H., Lazure, C., & Solomon, S. (1990). Granulins, a novel class of  
827 peptide from leukocytes. *Biochem Biophys Res Commun*, *173*(3), 1161-1168. doi:10.1016/s0006-  
828 291x(05)80908-8
- 829 Bateman, A., & Bennett, H. P. (1998). Granulins: the structure and function of an emerging family of  
830 growth factors. *J Endocrinol*, *158*(2), 145-151. doi:10.1677/joe.0.1580145
- 831 Bhopatkar, A. A., & Rangachari, V. (2021). Are granulins copper sequestering proteins? *Proteins*, *89*(4),  
832 450-461. doi:10.1002/prot.26031
- 833 Bhopatkar, A. A., Uversky, V. N., & Rangachari, V. (2020). Granulins modulate liquid-liquid phase  
834 separation and aggregation of the prion-like C-terminal domain of the neurodegeneration-  
835 associated protein TDP-43. *The Journal of biological chemistry*, *295*(8), 2506-2519.  
836 doi:10.1074/jbc.RA119.011501
- 837 Brangwynne, Clifford P., Tompa, P., & Pappu, Rohit V. (2015). Polymer physics of intracellular phase  
838 transitions. *Nature Physics*, *11*(11), 899-904. doi:10.1038/nphys3532
- 839 Buell, A. K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T. P., . . . Dobson, C. M.  
840 (2014). Solution conditions determine the relative importance of nucleation and growth processes  
841 in  $\alpha$ -synuclein aggregation. *Proc Natl Acad Sci U S A*, *111*(21), 7671-7676.  
842 doi:10.1073/pnas.1315346111
- 843 Buratti, E., & Baralle, F. E. (2008). Multiple roles of TDP-43 in gene expression, splicing regulation, and  
844 human disease. *Front Biosci*, *13*, 867-878. doi:10.2741/2727

- 845 Buratti, E., Dörk, T., Zuccato, E., Pagani, F., Romano, M., & Baralle, F. E. (2001). Nuclear factor TDP-  
846 43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. *Embo j*, *20*(7), 1774-  
847 1784. doi:10.1093/emboj/20.7.1774
- 848 Chitramuthu, B. P., Bennett, H. P. J., & Bateman, A. (2017). Progranulin: a new avenue towards the  
849 understanding and treatment of neurodegenerative disease. *Brain*, *140*(12), 3081-3104.  
850 doi:10.1093/brain/awx198
- 851 Choi, J.-M., Dar, F., & Pappu, R. V. (2019). LASSI: A lattice model for simulating phase transitions of  
852 multivalent proteins. *PLOS Computational Biology*, *15*(10), e1007028.  
853 doi:10.1371/journal.pcbi.1007028
- 854 Choi, J.-M., Holehouse, A. S., & Pappu, R. V. (2020). Physical Principles Underlying the Complex  
855 Biology of Intracellular Phase Transitions. *Annual Review of Biophysics*, *49*(1), 107-133.  
856 doi:10.1146/annurev-biophys-121219-081629
- 857 Chow, T. W., Miller, B. L., Hayashi, V. N., & Geschwind, D. H. (1999). Inheritance of Frontotemporal  
858 Dementia. *Archives of Neurology*, *56*(7), 817-822. doi:10.1001/archneur.56.7.817
- 859 Ciryam, P., Lambert-Smith, I. A., Bean, D. M., Freer, R., Cid, F., Tartaglia, G. G., . . . Yerbury, J. J.  
860 (2017). Spinal motor neuron protein supersaturation patterns are associated with inclusion body  
861 formation in ALS. *Proceedings of the National Academy of Sciences*, *114*(20), E3935.  
862 doi:10.1073/pnas.1613854114
- 863 Colombrita, C., Zennaro, E., Fallini, C., Weber, M., Sommacal, A., Buratti, E., . . . Ratti, A. (2009). TDP-  
864 43 is recruited to stress granules in conditions of oxidative insult. *Journal of Neurochemistry*,  
865 *111*(4), 1051-1061. doi:<https://doi.org/10.1111/j.1471-4159.2009.06383.x>
- 866 Conicella, A. E., Zerze, G. H., Mittal, J., & Fawzi, N. L. (2016). ALS Mutations Disrupt Phase Separation  
867 Mediated by  $\alpha$ -Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. *Structure*,  
868 *24*(9), 1537-1549. doi:10.1016/j.str.2016.07.007
- 869 Correia, A. S., Patel, P., Dutta, K., & Julien, J.-P. (2015). Inflammation Induces TDP-43 Mislocalization  
870 and Aggregation. *PLOS ONE*, *10*(10), e0140248-e0140248. doi:10.1371/journal.pone.0140248
- 871 Dean, D. N., Rana, P., Campbell, R. P., Ghosh, P., & Rangachari, V. (2018). Propagation of an A $\beta$   
872 Dodecamer Strain Involves a Three-Step Mechanism and a Key Intermediate. *Biophys J*, *114*(3),  
873 539-549. doi:10.1016/j.bpj.2017.11.3778
- 874 Düster, R., Kalthener, I. H., Schmitz, M., & Geyer, M. (2021). 1,6-Hexanediol, commonly used to  
875 dissolve liquid&#x2013;liquid phase separated condensates, directly impairs kinase and  
876 phosphatase activities. *Journal of Biological Chemistry*, *296*. doi:10.1016/j.jbc.2021.100260
- 877 Elia, L. P., Mason, A. R., Alijagic, A., & Finkbeiner, S. (2019). Genetic Regulation of Neuronal  
878 Progranulin Reveals a Critical Role for the Autophagy-Lysosome Pathway. *The Journal of*  
879 *Neuroscience*, *39*(17), 3332. doi:10.1523/JNEUROSCI.3498-17.2019
- 880 Erdős, G., & Dosztányi, Z. (2020). Analyzing Protein Disorder with IUPred2A. *Current Protocols in*  
881 *Bioinformatics*, *70*(1), e99. doi:<https://doi.org/10.1002/cpbi.99>
- 882 Fang, M. Y., Markmiller, S., Vu, A. Q., Javaherian, A., Dowdle, W. E., Jolivet, P., . . . Yeo, G. W.  
883 (2019). Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents  
884 Persistent TDP-43 Accumulation in ALS/FTD. *Neuron*, *103*(5), 802-819.e811.  
885 doi:10.1016/j.neuron.2019.05.048
- 886 Feneberg, E., Charles, P. D., Finelli, M. J., Scott, C., Kessler, B. M., Fischer, R., . . . Turner, M. R.  
887 (2020). Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP. *Brain*  
888 *Pathol*, e12923. doi:10.1111/bpa.12923
- 889 François-Moutal, L., Perez-Miller, S., Scott, D. D., Miranda, V. G., Mollasalehi, N., & Khanna, M.  
890 (2019). Structural Insights Into TDP-43 and Effects of Post-translational Modifications. *Frontiers*  
891 *in Molecular Neuroscience*, *12*(301). doi:10.3389/fnmol.2019.00301
- 892 Gao, X., Joselin, A. P., Wang, L., Kar, A., Ray, P., Bateman, A., . . . Wu, J. Y. (2010). Progranulin  
893 promotes neurite outgrowth and neuronal differentiation by regulating GSK-3 $\beta$ . *Protein Cell*,  
894 *1*(6), 552-562. doi:10.1007/s13238-010-0067-1



- 895 Gass, J., Lee, W. C., Cook, C., Finch, N., Stetler, C., Jansen-West, K., . . . Petrucelli, L. (2012).  
896 Progranulin regulates neuronal outgrowth independent of sortilin. *Mol Neurodegener*, 7, 33.  
897 doi:10.1186/1750-1326-7-33
- 898 Gasset-Rosa, F., Lu, S., Yu, H., Chen, C., Melamed, Z., Guo, L., . . . Cleveland, D. W. (2019).  
899 Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear  
900 Import, Loss of Nuclear TDP-43, and Cell Death. *Neuron*, 102(2), 339-357.e337.  
901 doi:10.1016/j.neuron.2019.02.038
- 902 Ghag, G., Holler, C. J., Taylor, G., Kukar, T. L., Uversky, V. N., & Rangachari, V. (2017). Disulfide  
903 bonds and disorder in granulin-3: An unusual handshake between structural stability and  
904 plasticity. *Protein Science*, 26(9), 1759-1772. doi:<https://doi.org/10.1002/pro.3212>
- 905 Gilks, N., Kedersha, N., Ayodele, M., Shen, L., Stoecklin, G., Dember, L. M., & Anderson, P. (2004).  
906 Stress Granule Assembly Is Mediated by Prion-like Aggregation of TIA-1. *Molecular Biology of*  
907 *the Cell*, 15(12), 5383-5398. doi:10.1091/mbc.e04-08-0715
- 908 Grossman, M. (2002). Frontotemporal dementia: a review. *J Int Neuropsychol Soc*, 8(4), 566-583.  
909 doi:10.1017/s1355617702814357
- 910 Guil, S., Long, J. C., & Cáceres, J. F. (2006). hnRNP A1 relocalization to the stress granules reflects a  
911 role in the stress response. *Mol Cell Biol*, 26(15), 5744-5758. doi:10.1128/mcb.00224-06
- 912 He, Z., & Bateman, A. (1999). <em>Progranulin</em>; Gene Expression Regulates Epithelial  
913 Cell Growth and Promotes Tumor Growth <em>in Vivo</em>. *Cancer Res*, 59(13),  
914 3222.
- 915 He, Z., & Bateman, A. (2003). Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor,  
916 acrogranin) mediates tissue repair and tumorigenesis. *J Mol Med*, 81(10), 600-612.
- 917 Herman Allison, B., Silva Afonso, M., Kelemen Sheri, E., Ray, M., Vrakas Christine, N., Burke Amy, C.,  
918 . . . Autieri Michael, V. (2019). Regulation of Stress Granule Formation by Inflammation,  
919 Vascular Injury, and Atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*,  
920 39(10), 2014-2027. doi:10.1161/ATVBAHA.119.313034
- 921 Holler, C. J., Taylor, G., Deng, Q., & Kukar, T. (2017). Intracellular Proteolysis of Progranulin Generates  
922 Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal  
923 Dementia Caused by GRN Mutations. *eNeuro*, 4(4). doi:10.1523/eneuro.0100-17.2017
- 924 Hoque, M., Mathews, M. B., & Pe'ery, T. (2010). Progranulin (granulin/epithelin precursor) and its  
925 constituent granulin repeats repress transcription from cellular promoters. *J Cell Physiol*, 223(1),  
926 224-233. doi:10.1002/jcp.22031
- 927 Horinokita, I., Hayashi, H., Oteki, R., Mizumura, R., Yamaguchi, T., Usui, A., . . . Takagi, N. (2019).  
928 Involvement of Progranulin and Granulin Expression in Inflammatory Responses after Cerebral  
929 Ischemia. *Int J Mol Sci*, 20(20). doi:10.3390/ijms20205210
- 930 Hu, F., Padukkavidana, T., Vægter, C. B., Brady, O. A., Zheng, Y., Mackenzie, I. R., . . . Strittmatter, S.  
931 M. (2010). Sortilin-mediated endocytosis determines levels of the frontotemporal dementia  
932 protein, progranulin. *Neuron*, 68(4), 654-667. doi:10.1016/j.neuron.2010.09.034
- 933 Igaz, L. M., Kwong, L. K., Chen-Plotkin, A., Winton, M. J., Unger, T. L., Xu, Y., . . . Lee, V. M. Y.  
934 (2009). Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features  
935 of TDP-43 Proteinopathies. *The Journal of biological chemistry*, 284(13), 8516-8524.  
936 doi:10.1074/jbc.M809462200
- 937 Igaz, L. M., Kwong, L. K., Xu, Y., Truax, A. C., Uryu, K., Neumann, M., . . . Lee, V. M. (2008).  
938 Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in  
939 brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral  
940 sclerosis. *Am J Pathol*, 173(1), 182-194. doi:10.2353/ajpath.2008.080003
- 941 Irwin, D. J., Cairns, N. J., Grossman, M., McMillan, C. T., Lee, E. B., Van Deerlin, V. M., . . .  
942 Trojanowski, J. Q. (2015). Frontotemporal lobar degeneration: defining phenotypic diversity  
943 through personalized medicine. *Acta Neuropathologica*, 129(4), 469-491. doi:10.1007/s00401-  
944 014-1380-1

- 945 Jian, J., Konopka, J., & Liu, C. (2013). Insights into the role of progranulin in immunity, infection, and  
946 inflammation. *Journal of leukocyte biology*, *93*(2), 199-208. doi:10.1189/jlb.0812429
- 947 Kao, A. W., McKay, A., Singh, P. P., Brunet, A., & Huang, E. J. (2017). Progranulin, lysosomal  
948 regulation and neurodegenerative disease. *Nat Rev Neurosci*, *18*(6), 325-333.  
949 doi:10.1038/nrn.2017.36
- 950 Kaur, T., Raju, M., Alshareedah, I., Davis, R. B., Potoyan, D. A., & Banerjee, P. R. (2021). Sequence-  
951 encoded and composition-dependent protein-RNA interactions control multiphasic condensate  
952 morphologies. *Nature Communications*, *12*(1), 872. doi:10.1038/s41467-021-21089-4
- 953 Kedersha, N., Cho, M. R., Li, W., Yacono, P. W., Chen, S., Gilks, N., . . . Anderson, P. (2000). Dynamic  
954 shuttling of TIA-1 accompanies the recruitment of mRNA to mammalian stress granules. *The*  
955 *Journal of cell biology*, *151*(6), 1257-1268. doi:10.1083/jcb.151.6.1257
- 956 Khalfallah, Y., Kuta, R., Grasmuck, C., Prat, A., Durham, H. D., & Vande Velde, C. (2018). TDP-43  
957 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. *Scientific*  
958 *Reports*, *8*(1), 7551. doi:10.1038/s41598-018-25767-0
- 959 Lee, C. W., Stankowski, J. N., Chew, J., Cook, C. N., Lam, Y.-W., Almeida, S., . . . Petrucelli, L. (2017).  
960 The lysosomal protein cathepsin L is a progranulin protease. *Molecular Neurodegeneration*,  
961 *12*(1), 55. doi:10.1186/s13024-017-0196-6
- 962 Lee, C. W., Stankowski, J. N., Chew, J., Cook, C. N., Lam, Y. W., Almeida, S., . . . Petrucelli, L. (2017).  
963 The lysosomal protein cathepsin L is a progranulin protease. *Mol Neurodegener*, *12*(1), 55.  
964 doi:10.1186/s13024-017-0196-6
- 965 Li, H.-R., Chiang, W.-C., Chou, P.-C., Wang, W.-J., & Huang, J.-R. (2018). TAR DNA-binding protein  
966 43 (TDP-43) liquid-liquid phase separation is mediated by just a few aromatic residues. *The*  
967 *Journal of biological chemistry*, *293*(16), 6090-6098. doi:10.1074/jbc.AC117.001037
- 968 Li, H. R., Chen, T. C., Hsiao, C. L., Shi, L., Chou, C. Y., & Huang, J. R. (2018). The physical forces  
969 mediating self-association and phase-separation in the C-terminal domain of TDP-43. *Biochim*  
970 *Biophys Acta Proteins Proteom*, *1866*(2), 214-223. doi:10.1016/j.bbapap.2017.10.001
- 971 Lim, L., Wei, Y., Lu, Y., & Song, J. (2016). ALS-Causing Mutations Significantly Perturb the Self-  
972 Assembly and Interaction with Nucleic Acid of the Intrinsically Disordered Prion-Like Domain  
973 of TDP-43. *PLoS Biol*, *14*(1), e1002338. doi:10.1371/journal.pbio.1002338
- 974 Liu-Yesucevitz, L., Bilgutay, A., Zhang, Y.-J., Vanderwyde, T., Citro, A., Mehta, T., . . . Wolozin, B.  
975 (2010). Tar DNA Binding Protein-43 (TDP-43) Associates with Stress Granules: Analysis of  
976 Cultured Cells and Pathological Brain Tissue. *PLOS ONE*, *5*(10), e13250.  
977 doi:10.1371/journal.pone.0013250
- 978 López-Mirabal, H. R., & Winther, J. R. (2008). Redox characteristics of the eukaryotic cytosol.  
979 *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, *1783*(4), 629-640.  
980 doi:<https://doi.org/10.1016/j.bbamcr.2007.10.013>
- 981 Mackenzie, I. R., Munoz, D. G., Kusaka, H., Yokota, O., Ishihara, K., Roeber, S., . . . Neumann, M.  
982 (2011). Distinct pathological subtypes of FTL-D-FUS. *Acta Neuropathol*, *121*(2), 207-218.  
983 doi:10.1007/s00401-010-0764-0
- 984 Mackenzie, I. R. A., & Rademakers, R. (2008). The role of transactive response DNA-binding protein-43  
985 in amyotrophic lateral sclerosis and frontotemporal dementia. *Current opinion in neurology*,  
986 *21*(6), 693-700. doi:10.1097/WCO.0b013e3283168d1d
- 987 Majumdar, A., Dogra, P., Maity, S., & Mukhopadhyay, S. (2019). Liquid-Liquid Phase Separation Is  
988 Driven by Large-Scale Conformational Unwinding and Fluctuations of Intrinsically Disordered  
989 Protein Molecules. *The Journal of Physical Chemistry Letters*, *10*(14), 3929-3936.  
990 doi:10.1021/acs.jpcclett.9b01731
- 991 Malaspina, A., Kaushik, N., & de Belleruche, J. (2001). Differential expression of 14 genes in  
992 amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. *J Neurochem*,  
993 *77*(1), 132-145. doi:10.1046/j.1471-4159.2001.t01-1-00231.x
- 994 Mao, Q., Wang, D., Li, Y., Kohler, M., Wilson, J., Parton, Z., . . . Bigio, E. H. (2017). Disease and  
995 Region Specificity of Granulin Immunopositivities in Alzheimer Disease and Frontotemporal

- 996 Lobar Degeneration. *Journal of Neuropathology & Experimental Neurology*, 76(11), 957-968.  
997 doi:10.1093/jnen/nlx085
- 998 Mazmanian, K., Sargsyan, K., Grauffel, C., Dudev, T., & Lim, C. (2016). Preferred Hydrogen-Bonding  
999 Partners of Cysteine: Implications for Regulating Cys Functions. *The Journal of Physical*  
1000 *Chemistry B*, 120(39), 10288-10296. doi:10.1021/acs.jpcc.6b08109
- 1001 Mészáros, B., Erdos, G., & Dosztányi, Z. (2018). IUPred2A: context-dependent prediction of protein  
1002 disorder as a function of redox state and protein binding. *Nucleic Acids Res*, 46(W1), W329-  
1003 w337. doi:10.1093/nar/gky384
- 1004 Muiznieks, L. D., Sharpe, S., Pomès, R., & Keeley, F. W. (2018). Role of Liquid-Liquid Phase  
1005 Separation in Assembly of Elastin and Other Extracellular Matrix Proteins. *Journal of Molecular*  
1006 *Biology*, 430(23), 4741-4753. doi:<https://doi.org/10.1016/j.jmb.2018.06.010>
- 1007 Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., . . . Lee, V.  
1008 M. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral  
1009 sclerosis. *Science*, 314(5796), 130-133. doi:10.1126/science.1134108
- 1010 Nunes, C., Mestre, I., Marcelo, A., Koppenol, R., Matos, C. A., & Nóbrega, C. (2019). MSGP: the first  
1011 database of the protein components of the mammalian stress granules. *Database*, 2019.  
1012 doi:10.1093/database/baz031
- 1013 Pak, C. W., Kosno, M., Holehouse, A. S., Padrick, S. B., Mittal, A., Ali, R., . . . Rosen, M. K. (2016).  
1014 Sequence Determinants of Intracellular Phase Separation by Complex Coacervation of a  
1015 Disordered Protein. *Mol Cell*, 63(1), 72-85. doi:10.1016/j.molcel.2016.05.042
- 1016 Park, B., Buti, L., Lee, S., Matsuwaki, T., Spooner, E., Brinkmann, M. M., . . . Ploegh, H. L. (2011).  
1017 Granulin is a soluble cofactor for toll-like receptor 9 signaling. *Immunity*, 34(4), 505-513.  
1018 doi:10.1016/j.immuni.2011.01.018
- 1019 Plowman, G. D., Green, J. M., Neubauer, M. G., Buckley, S. D., McDonald, V. L., Todaro, G. J., &  
1020 Shoyab, M. (1992). The epithelin precursor encodes two proteins with opposing activities on  
1021 epithelial cell growth. *The Journal of biological chemistry*, 267(18), 13073-13078.
- 1022 Prasad, A., Bharathi, V., Sivalingam, V., Girdhar, A., & Patel, B. K. (2019). Molecular Mechanisms of  
1023 TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis. *Frontiers in Molecular*  
1024 *Neuroscience*, 12(25). doi:10.3389/fnmol.2019.00025
- 1025 Protter, D. S. W., & Parker, R. (2016). Principles and Properties of Stress Granules. *Trends in cell*  
1026 *biology*, 26(9), 668-679. doi:10.1016/j.tcb.2016.05.004
- 1027 Root, J., Merino, P., Nuckols, A., Johnson, M., & Kukar, T. (2021). Lysosome dysfunction as a cause of  
1028 neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral  
1029 sclerosis. *Neurobiology of Disease*, 154, 105360. doi:<https://doi.org/10.1016/j.nbd.2021.105360>
- 1030 Ruff, K. M., Dar, F., & Pappu, R. V. (2021). Ligand effects on phase separation of multivalent  
1031 macromolecules. *Proceedings of the National Academy of Sciences*, 118(10), e2017184118.  
1032 doi:10.1073/pnas.2017184118
- 1033 Ryan, C. L., Baranowski, D. C., Chitramuthu, B. P., Malik, S., Li, Z., Cao, M., . . . Bateman, A. (2009).  
1034 Progranulin is expressed within motor neurons and promotes neuronal cell survival. *BMC*  
1035 *Neurosci*, 10, 130. doi:10.1186/1471-2202-10-130
- 1036 Salazar, D. A., Butler, V. J., Argouarch, A. R., Hsu, T.-Y., Mason, A., Nakamura, A., . . . Kao, A. W.  
1037 (2015). The Progranulin Cleavage Products, Granulins, Exacerbate TDP-43 Toxicity and Increase  
1038 TDP-43 Levels. *The Journal of Neuroscience*, 35(25), 9315. doi:10.1523/JNEUROSCI.4808-  
1039 14.2015
- 1040 Sama, R. R. K., Ward, C. L., Kaushansky, L. J., Lemay, N., Ishigaki, S., Urano, F., & Bosco, D. A.  
1041 (2013). FUS/TLS assembles into stress granules and is a prosurvival factor during hyperosmolar  
1042 stress. *J Cell Physiol*, 228(11), 2222-2231. doi:10.1002/jcp.24395
- 1043 Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A., Fox, N. C., & van Swieten, J. C. (2011). Clinical, genetic  
1044 and pathological heterogeneity of frontotemporal dementia: a review. *J Neurol Neurosurg*  
1045 *Psychiatry*, 82(5), 476-486. doi:10.1136/jnnp.2010.212225

- 1046 Shoyab, M., McDonald, V. L., Byles, C., Todaro, G. J., & Plowman, G. D. (1990). Epithelins 1 and 2:  
1047 isolation and characterization of two cysteine-rich growth-modulating proteins. *Proc Natl Acad*  
1048 *Sci U S A*, 87(20), 7912-7916. doi:10.1073/pnas.87.20.7912
- 1049 Shulga, N., & Goldfarb, D. S. (2003). Binding dynamics of structural nucleoporins govern nuclear pore  
1050 complex permeability and may mediate channel gating. *Mol Cell Biol*, 23(2), 534-542.  
1051 doi:10.1128/mcb.23.2.534-542.2003
- 1052 Sun, Y., & Chakrabartty, A. (2017). Phase to Phase with TDP-43. *Biochemistry*, 56(6), 809-823.  
1053 doi:10.1021/acs.biochem.6b01088
- 1054 Tanaka, Y., Suzuki, G., Matsuwaki, T., Hosokawa, M., Serrano, G., Beach, T. G., . . . Nishihara, M.  
1055 (2017). Progranulin regulates lysosomal function and biogenesis through acidification of  
1056 lysosomes. *Hum Mol Genet*, 26(5), 969-988. doi:10.1093/hmg/ddx011
- 1057 Ungurs, M. J., Sinden, N. J., & Stockley, R. A. (2014). Progranulin is a substrate for neutrophil-elastase  
1058 and proteinase-3 in the airway and its concentration correlates with mediators of airway  
1059 inflammation in COPD. *Am J Physiol Lung Cell Mol Physiol*, 306(1), L80-87.  
1060 doi:10.1152/ajplung.00221.2013
- 1061 Uversky, V. N. (2017). Protein intrinsic disorder-based liquid-liquid phase transitions in biological  
1062 systems: Complex coacervates and membrane-less organelles. *Advances in Colloid and Interface*  
1063 *Science*, 239, 97-114. doi:<https://doi.org/10.1016/j.cis.2016.05.012>
- 1064 Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., . . .  
1065 Robberecht, W. (2008). Progranulin functions as a neurotrophic factor to regulate neurite  
1066 outgrowth and enhance neuronal survival. *The Journal of cell biology*, 181(1), 37-41.  
1067 doi:10.1083/jcb.200712039
- 1068 Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van Swieten, J., . . .  
1069 Robberecht, W. (2008). Progranulin functions as a neurotrophic factor to regulate neurite  
1070 outgrowth and enhance neuronal survival. *The Journal of cell biology*, 181(1), 37-41.  
1071 doi:10.1083/jcb.200712039
- 1072 van der Zee, J., Le Ber, I., Maurer-Stroh, S., Engelborghs, S., Gijselinck, I., Camuzat, A., . . . Van  
1073 Broeckhoven, C. (2007). Mutations other than null mutations producing a pathogenic loss of  
1074 progranulin in frontotemporal dementia. *Hum Mutat*, 28(4), 416. doi:10.1002/humu.9484
- 1075 Van Treeck, B., Protter, D. S. W., Matheny, T., Khong, A., Link, C. D., & Parker, R. (2018). RNA self-  
1076 assembly contributes to stress granule formation and defining the stress granule transcriptome.  
1077 *Proceedings of the National Academy of Sciences*, 115(11), 2734. doi:10.1073/pnas.1800038115
- 1078 Wang, C., Duan, Y., Duan, G., Wang, Q., Zhang, K., Deng, X., . . . Fang, Y. (2020). Stress Induces  
1079 Dynamic, Cytotoxicity-Antagonizing TDP-43 Nuclear Bodies via Paraspeckle LncRNA NEAT1-  
1080 Mediated Liquid-Liquid Phase Separation. *Mol Cell*, 79(3), 443-458.e447.  
1081 doi:<https://doi.org/10.1016/j.molcel.2020.06.019>
- 1082 Wang, H. Y., Wang, I. F., Bose, J., & Shen, C. K. (2004). Structural diversity and functional implications  
1083 of the eukaryotic TDP gene family. *Genomics*, 83(1), 130-139. doi:10.1016/s0888-  
1084 7543(03)00214-3
- 1085 Wang, J., Choi, J.-M., Holehouse, A. S., Lee, H. O., Zhang, X., Jahnel, M., . . . Hyman, A. A. (2018). A  
1086 Molecular Grammar Governing the Driving Forces for Phase Separation of Prion-like RNA  
1087 Binding Proteins. *Cell*, 174(3), 688-699.e616. doi:<https://doi.org/10.1016/j.cell.2018.06.006>
- 1088 Ward, M. E., Chen, R., Huang, H. Y., Ludwig, C., Telpoukhovskaia, M., Taubes, A., . . . Green, A. J.  
1089 (2017). Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid  
1090 lipofuscinosis. *Sci Transl Med*, 9(385). doi:10.1126/scitranslmed.aah5642
- 1091 Watanabe, S., Inami, H., Oiwa, K., Murata, Y., Sakai, S., Komine, O., . . . Yamanaka, K. (2020).  
1092 Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic  
1093 aggregation of TAR DNA-binding protein 43. *Cell Death & Disease*, 11(10), 909.  
1094 doi:10.1038/s41419-020-03116-2
- 1095 Wheeler, J. R., Matheny, T., Jain, S., Abrisch, R., & Parker, R. (2016). Distinct stages in stress granule  
1096 assembly and disassembly. *eLife*, 5, e18413. doi:10.7554/eLife.18413

- 1097 Wright, P. E., & Dyson, H. J. (2015). Intrinsically disordered proteins in cellular signalling and  
1098 regulation. *Nature Reviews Molecular Cell Biology*, 16(1), 18-29. doi:10.1038/nrm3920
- 1099 Xiao, S., Sanelli, T., Chiang, H., Sun, Y., Chakrabarty, A., Keith, J., . . . Robertson, J. (2015). Low  
1100 molecular weight species of TDP-43 generated by abnormal splicing form inclusions in  
1101 amyotrophic lateral sclerosis and result in motor neuron death. *Acta Neuropathol*, 130(1), 49-61.  
1102 doi:10.1007/s00401-015-1412-5
- 1103 Xue, C., Lin, T. Y., Chang, D., & Guo, Z. Thioflavin T as an amyloid dye: fibril quantification, optimal  
1104 concentration and effect on aggregation. *Royal Society Open Science*, 4(1), 160696.  
1105 doi:10.1098/rsos.160696
- 1106 Yang, P., Mathieu, C., Kolaitis, R.-M., Zhang, P., Messing, J., Yurtsever, U., . . . Taylor, J. P. (2020).  
1107 G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble Stress Granules. *Cell*,  
1108 181(2), 325-345.e328. doi:<https://doi.org/10.1016/j.cell.2020.03.046>
- 1109 Zhang, T., Du, H., Santos, M. N., Wu, X., Reinheckel, T., & Hu, F. (2021). Differential regulation of  
1110 progranulin derived granulin peptides. *bioRxiv*, 2021.2001.2008.425959.  
1111 doi:10.1101/2021.01.08.425959
- 1112 Zhang, Y.-J., Xu, Y.-F., Cook, C., Gendron, T. F., Roettges, P., Link, C. D., . . . Petrucelli, L. (2009).  
1113 Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. *Proceedings of the*  
1114 *National Academy of Sciences*, 106(18), 7607. doi:10.1073/pnas.0900688106
- 1115 Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., . . . Ding, A. (2002). Conversion of  
1116 proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. *Cell*,  
1117 111(6), 867-878. doi:10.1016/s0092-8674(02)01141-8

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131


1132

1133

1134

1135 **SUPPLEMENTARY FIGURES**

1136 **Figure S1**



1137

1138 **Figure S1. Localization of GRNs and PrLD within SGs.** a-b) Immunofluorescence imaging of PrLD  
1139 along with GRNs using TIA-1 antibodies with and without stress. PrLD-SBFP2 colocalization study with  
1140 TIA1 in non-stressed cells (a) and sodium arsenite-induced stressed cells (b) (cyan arrows). C) Manders  
1141 tM1 derived from five independently observed cells. d-e) Colocalization analysis of GRNs labeled with  
1142 Hilyte-647, PrLD and/or TIA-1 without stress (d) and with stress (e). Cyan colored arrows indicate the  
1143 colocalization of PrLD and TIA1, while pink colored arrows represent colocalization of PrLD and GRNs.  
1144 A three-way colocalization between GRN, PrLD and TIA1 was not observed. Scale bar represents 5  $\mu$ m.

1145

1146


1147

1148

1149

1150

1151 **Figure S2**



1152

1153 **Figure S2. Live cell analysis of SGs formed by full-length TDP-43 in SH-SY5Y cells.** Wild-type TDP43  
1154 tdTomato with and without stress in SH-SY5Y cells (a). White arrows indicate the SGs formation in sodium  
1155 arsenite treated cells. Normalized FRAP data of TDP-43 SGs and solid-like aggregates in sodium arsenite  
1156 treated cells (—) and untreated cells (—) respectively. c-d) Confocal images of wtTDP43tdTomato  
1157 transfected cells in presence of GRNs without (c) and with stress (d). Arrows in stressed cells indicate SGs  
1158 containing TDP-43. No colocalization between GRNs and TDP-43 was observed. Scale bar represents 5  
1159 μm.

1160

1161

1162


1163

1164

1165

1166

1167 **Figure S3**



1168

1169

1170 **Figure S3. Redox-controlled disorder propensities of PrLD and GRNs.** Structural disorder score of  
1171 PrLD and GRNs estimated in a redox-dependent context using IUPred2A. Redox sensitive regions (shaded,  
1172 purple) are calculated based on differences in disorder scores of the oxidized (red) and reduced (dark purple)  
1173 forms of the proteins. Calculated scores above the 0.5 threshold signify disorder within the region. Cysteine  
1174 residues are marked within the sequence of GRNs (yellow bars).

1175

1176

1177

1178

1179


1180

1181



1182

1183 **Figure S4**



1184


1185 **Figure S4. Biophysical characterization of GRNs.** a) Far-UV circular dichroism (CD) spectra of GRN-2  
 1186 and rGRN-2 displaying a characteristic profile of a structure dominated by random coils. b) SDS-PAGE  
 1187 analysis of GRN-2 and rGRN-2 the presence or absence of  $\beta$ -mercaptoethanol ( $\beta$ ME) performed under  
 1188 denaturing conditions. c) MALDI-ToF MS graph of GRN-2 shows a peak at 6581.7 Da which corresponds  
 1189 to the monomeric form of the protein (theoretical mass: 6590.5 Da). Ellman's assay performed on the  
 1190 fraction reveals the presence of 1-2 free thiols. d) Free thiols in GRN-2 and rGRN-2 determined by  
 1191 alkylation with iodoacetamide and analyzed using MALDI-ToF MS. Alkylation of a free thiol by  
 1192 iodoacetamide leads to the addition of a thioether adduct (+ 59.0 Da). e) Far-UV CD spectra of the redox  
 1193 forms of GRN-3 and GRN-5. f) SDS-PAGE analysis of the mutant forms of GRN-2; GRN-2(+/-) and GRN-  
 1194 2(C/A) in the presence or absence of  $\beta$ ME under denaturing conditions. g) Alkylated forms of GRN-2 were  
 1195 generated by either capping the two free-thiols in the oxidized form (GRN-2 2alk) or all twelve thiols in  
 1196 the reduced form (GRN-2 12alk) using iodoacetamide and were subsequently subjected to MALDI-ToF  
 1197 MS for analysis. h) Characterization of GRN-2(+/-) using MALDI-ToF MS shows a peak at 6531.7 Da  
 1198 corresponding to monomeric form of the protein (theoretical mass: 6536.4 Da). Two additional peaks were  
 1199 observed beside this corresponding to two, highly oxidized sulfur atoms in the cysteine (Sulfur-dioxide;  
 1200 +32 Da). Ellman's assay reveals the presence of about 1-free thiol in the protein i) Estimation of free thiols  
 1201 in the oxidized and reduced form of GRN-2(+/-) using alkylation assay. j) Characterization of GRN-2(C/A)  
 1202 using MALDI-ToF MS shows a peak at 6206.7 Da corresponding to monomeric form of the protein  
 1203 (theoretical mass: 6205.8 Da). k) Alkylation assay performed on GRN-2(+/-) analyzed using MALDI-ToF  
 1204 MS.

1205

1206

1207

1208 **Figure S5**



1209

1210 **Figure S5. Interaction of GRN-7 with PrLD.** a) Sequence of GRN-7 annotated with acidic and basic

1211 residues and the net charge at neutral pH. MALDI-ToF MS spectrum of oxidized GRN-7 shows a peak at

1212 6605.8 Da corresponding to the monomeric protein (theoretical mass: 6615.4 Da). b) The effect of 40  $\mu$ M

1213 GRN-7 on the aggregation of 20  $\mu$ M PrLD was monitored in the presence of 15  $\mu$ M ThT for a period of 36


1214 h at 37°C under quiescent conditions. c) DIC micrograph of the sample containing GRN-7 and PrLD from

1215 b) showing the presence of solid-aggregates (liquid-solid phase separation, saffron box). Scale bar

1216 represents 20  $\mu$ m.

1217

1218 **Figure S6**



1219

1220 **Figure S6. Reduction of GRN-2 with alternative reducing agents.** a-b) Confocal micrographs of

1221 mixtures containing 20  $\mu$ M PrLD with 40  $\mu$ M rGRN-2 reduced using 12 molar excess of dithiothreitol


1222 (DTT) (a) or glutathione (GSH) (b). Reactions contain 1% fluorophore labeled proteins for microscopic

1223 visualization. Reactions were initiated at room temperature and imaged within 15 minutes.

1224

1225

1226 **Figure S7**




1227

1228 **Figure S7. Formation of ThT-positive species of PrLD in presence of GRN-2.** The amyloid formation  
1229 of 20  $\mu\text{M}$  TDP-43 PrLD alone ( $\bullet$ ) or in presence of varying concentrations (2-40  $\mu\text{M}$ ) of GRN-2 or rGRN-  
1230 2, buffered in 20 mM MES, pH 6.0, monitored using 15  $\mu\text{M}$  ThT for a period of 60 h at 37  $^{\circ}\text{C}$  under  
1231 quiescent conditions.

1232

1233 **Figure S8**



1234

1235 **Figure S8. Comparison of the droplet area distributions of GRN-2 and its mutants.** Micrographs of  
1236 reactions depicted in Fig 5 were subjected to droplet area distribution analysis as described previously using  
1237 the imageJ platform. Samples of 20  $\mu\text{M}$  PrLD with 40  $\mu\text{M}$  GRN-2 (gray), GRN-2(+/-) (red), rGRN-2(+/-)  
1238 (purple) and GRN-2(C/A) (green) were considered for analysis with a minimum of 100 droplets  
1239 enumerated. The normal distribution curves for each sample depicted were generated using Origin 8.5  
1240 graphing software.